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A B S T R A C T
Background
Malaria causes ill health and death in Africa. Treating illness promptly with artemisinin-based combination therapy (ACT) is likely to
cure people and avoid the disease progressing to more severe forms and death. In many countries, ACT use remains low. Part of the
problem is that most people seek treatment from the retail sector where ACTs are expensive; this expense is a barrier to their use.
The Global Fund and other international organisations are subsidising the cost of ACTs for private retail providers to improve access to
ACTs. The subsidy was initially organised through a stand-alone initiative, called the Affordable Medicines Facility-malaria (AMFm),
but has since been integrated into the Global Fund core grant management and financial processes.
Objectives
To assess the effect of programmes that include ACT price subsidies for private retailers on ACT use, availability, price and market
share.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 1, The Cochrane Library, including the
Cochrane Effective Practice andOrganisation of Care (EPOC)Group Specialised Register);MEDLINE (OvidSP), EMBASE (OvidSP),
CINAHL (EbscoHost), EconLit (ProQuest), Global Health (OvidSP), Regional Indexes (Global Health Library, WHO), LILACS
(GlobalHealth Library,WHO), ScienceCitation Index andSocial SciencesCitation Index (ISIWebof Science) andHealthManagement
(ProQuest). All databases were searched February 2015, except for Health Management which was searched November 2013, without
any date, language or publication status restrictions. We also searched the International Clinical Trials Registry Platform (ICTRP;
WHO), ClinicalTrials.gov (NIH) and various grey literature sources. We also conducted a cited reference search for all included studies
in ISI Web of Knowledge, checked references of identified articles and contacted authors to identify additional studies.
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Selection criteria
Randomised trials, non-randomised trials, controlled before-after studies and interrupted-time-series studies that compared the effects
of ACT price subsidies for private retailers to no subsidies or alternative ACT financing mechanisms were eligible for inclusion. Two
authors independently screened and selected studies for inclusion.
Data collection and analysis
Two review authors independently extracted data, assessed study risk of bias and confidence in effect estimates (certainty of evidence)
using Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
Main results
We included four trials (two cluster-randomised trials reported in three articles and two non-randomised cluster trials). Three trials
assessed retail sector ACT subsidies combined with supportive interventions (retail outlet provider training, community awareness and
mass media campaigns). One trial assessed vouchers provided to households to purchase subsidised ACTs. Price subsidies ranged from
80% to 95%. One trial enrolled children under five years of age; the other three trials studied people of all age groups. The studies
were done in rural districts in East Africa (Kenya, Uganda and Tanzania).
In this East Africa setting, these ACT subsidy programmes increased the percentage of children under five years of age receiving ACTs
on the day, or following day, of fever onset by 25 percentage points (95% confidence interval (CI) 14.1 to 35.9 percentage points; 1
study, high certainty evidence). This suggests that in practice, among febrile children under five years of age with an ACT usage rate
of 5% without a subsidy, subsidy programmes would increase usage by between 19% and 41% over a one year period.
The ACT subsidy programmes increased the percentage of retail outlets stocking ACTs for children under five years of age by 31.9
percentage points (95% CI 26.3 to 37.5 percentage points; 1 study, high certainty evidence). Effects on ACT stocking for patients of
any age is unknown because the certainty of evidence was very low.
The ACT subsidy programmes decreased the median cost of ACTs for children under five years of age by US$ 0.84 (median cost per
ACT course without subsidy: US$ 1.08 versus with subsidy: US$ 0.24; 1 study, high certainty evidence).
The ACT subsidy programmes increased the market share of ACTs for children under five years of age by between 23.6 and 63.0
percentage points (1 study, high certainty evidence).
The ACT subsidy programmes decreased the use of older antimalarial drugs (such as amodiaquine and sulphadoxine-pyrimethamine)
among children under five years of age by 10.4 percentage points (95% CI 3.9 to 16.9 percentage points; 1 study, high certainty
evidence).
None of the three studies of ACT subsidies reported the number of patients treated who had confirmed malaria.
Vouchers increased the likelihood that an illness is treated with an ACT by 16 to 23 percentage points; however, vouchers were associated
with a high rate of over-treatment of malaria (only 56% of patients taking ACTs from the drug shop tested positive for malaria under
the 92% subsidy; 1 study, high certainty evidence).
Authors’ conclusions
Programmes that include substantive subsidies for private sector retailers combined with training of providers and social marketing
improved use and availability of ACTs for children under five years of age with suspectedmalaria in research studies from three countries
in East Africa. These programmes also reduced prices of ACTs, improvedmarket share of ACTs and reduced the use of older antimalarial
drugs among febrile children under five years of age. The research evaluates drug delivery but does not assess whether the patients had
confirmed (parasite-diagnosed) malaria. None of the included studies assessed patient outcomes; it is therefore not known whether the
effects seen in the studies would translate to an impact on health.
P L A I N L A N G U A G E S U M M A R Y
Subsidising artemisinin-based combination therapy in drug shops and pharmacies
We conducted a review of the effect of subsidising artemisinin-based combination therapy (ACT) drugs for malaria. We searched for
all relevant studies up to February 2015 and identified four. Our findings are summarised below.
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Background
Malaria causes ill health and death in Africa, particularly in children under five years of age and poor rural populations. The World
Health Organization recommends that people use ACT to treat malaria. ACT drugs are available at shops and pharmacies, but these
drugs are expensive and people often choose cheaper, older, less effective drugs instead. The Global Fund and other international
organisations have therefore decided to subsidise the cost of ACT drugs so that people can buy them from shops and pharmacies at
prices similar to, or lower than, those of the older, less effective drugs.
What is the effect of delivery programmes that subsidise ACT prices?
We included four studies. One study looked at the effect of subsidising ACT drugs for children under five years of age and three
studies looked at subsidising ACT drugs for people of all ages. All studies were from rural districts in East Africa (Kenya, Uganda and
Tanzania). ACT price subsidies were accompanied with activities (such as staff training at shops and pharmacies, community awareness
and mass media campaigns) to promote appropriate use of antimalarial drugs in all except one study. In all four studies, the effect of
subsidising the drugs was compared to not subsidising the drugs. Price subsidies ranged from 80% to 95% of the actual price; vouchers
to households were used in one study.
The findings from these studies indicate that ACT subsidy programmes:
(i) lead to a substantial increase in the number of children under five years of age who used ACTs when they had a fever (high certainty
evidence);
(ii) lead to a substantial increase in the number of shops that stocked ACTs for children under five years of age (high certainty evidence);
we could not draw any conclusion on the effect on the number of shops that stocked ACTs for patients of any age because the quality
of evidence was very low;
(iii) lead to a substantial decrease in the price of ACTs for children under five years of age (high certainty evidence);
(iv) lead to a substantial increase in the market share of ACTs for children under five years of age (high certainty evidence); and
(v) lead to a decrease in the use of older, less effective antimalarials among children under five years of age (high certainty evidence).
None of the studies measured whether the subsidy programmes led to any harmful effects (such as the inappropriate use of ACTs, in
other words people who receive ACTs but do not actually have malaria).
The review findings also showed that subsidising ACT prices using vouchers lead to an increase in the likelihood that an illness was
treated with an ACT among people seeking treatment for fever or suspected malaria. However, vouchers also lead to an increase in
inappropriate use of ACTs (high certainty evidence).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Effects of retail sector ACT subsidy programmes on ACT use, availability, price and market share
Population: Patients seeking treatment for suspected uncomplicated malaria
Settings: Rural districts in East Africa (Kenya, Uganda, Tanzania)
Intervention: Retail sector ACT price subsidies plus supportive interventions (retail outlet provider training, community awareness and mass media campaigns)
Comparison: Standard practice (no subsidies)
Outcomes Illustrative comparative risksa (95% CI) Absolute difference (95% CI) Number of participants
(studies)
GRADE certainty of the evi-
dence
Assumed risk Corresponding risk
No ACT subsidy ACT subsidy
ACT use (percentage of chil-
dren under 5 years receiving
ACT on the same day or fol-
lowing day of fever onset)
Follow-up: 1 year
5.3%1 30.3%
(19.4% to 41.2%)b,2
25%
(14.1% to 35.9%)3,4,5
2,6626
(1 study)
⊕⊕⊕⊕
High
ACT availability (percentage
of outlets stocking ACTs for
children under 5 years)
Follow-up: 1 year
<0.5% 32.4%
(22.5% to 41.8%)7
31.9%
(26.3% to 37.5%)
1 study
(2 articles)
⊕⊕⊕⊕
High
ACT availability (percentage
of outlets stocking at least one
ACT for patients of any age)
Follow-up: 1 year
0.5% 72.7%
(65.5% to 79.8%
72.2%
(65.0% to 79.3%)8
1 study ⊕
Very low9
ACT price (change in ACT
prices for children under 5
years)c
Follow-up: 1 year
Median cost per ACT course:
US$ 1.0810
Median cost per ACT course:
US$ 0.2411−14
US$ 0.84 (IQR not estimable) 1 study ⊕⊕⊕⊕
High
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ACT market share (volume of
ACTs purchased as a propor-
tion of all antimalarials pur-
chased; all age groups)
Follow-up period: 1 year
Range: 0% to 1.0%15 Range: 25.4% to 65.0%16,17 Range 23.6% to 63.0% 1 study
(2 articles)
⊕⊕⊕⊕
High
Use of older antimalarials
(amodiaquine, sulphadoxine-
pyrimethamine; children under
5 years)
Follow-up period: 1 year
34.4%18 24.0%
(17.5% to 30.5%)19
-10.4%
(-3.9% to -16.9%)
1 study ⊕⊕⊕⊕
High
Adverse effects (such as
the number of people receiv-
ing ACTs who do not have
malaria)
Not measured Not measured Not estimable 3 studies Not estimable
ACT = artemisinin-based combination therapy; CI = confidence interval; IQR = interquartile range
aThe basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
bThis suggests that among febrile children with an expected ACT usage rate of 5% without subsidy, subsidy programmes would increase usage by between 19% and 41%
cCosts include only prices paid by patients to purchase ACTs. Costing based on US$-to-Kenyan shillings exchange rate for 1 November 2008
About the certainty of the evidence (GRADE)∗
High: This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different† is low.
Moderate: This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different† is moderate.
Low: This research provides some indication of the likely effect. However, the likelihood that it will be substantially different† is high.
Very low: This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different† is very high
∗This is sometimes referred to as ‘ quality of evidence’ or ‘ confidence in the estimate’
†Substantially different = a large enough difference that it might affect a decision
1Based on Kangwana 2011 baseline values.
2Based on Kangwana 2011. The second study, Talisuna 2012, reported an absolute change of 16%, but with no baseline data or
confidence intervals. Using baselines from Kangwana 2011 (5.3%) gives 20.3% ACT use in Talisuna 2012, which is consistent with the
findings of Kangwana 2011.
3Kangwana 2011: there was no correlation between socioeconomic status and use of artemether-lumefantrine (P = 0.875) or Tibamal
(subsidised artemether-lumefantrine; P = 0.745).
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4Talisuna 2012: Children under 5 years of age: odds ratio 10.0 (4.96 to 18.86); All age groups: patients in the intervention districts had
a six-fold increase in ACT use relative to the control district (95% CI 4.22 to 8.44). Use of ACT was higher in the highest socioeconomic
status stratum compared to the lowest stratum (odds ratio 2.4, 95% CI 1.72 to 3.35, p<0.001); the certainty of evidence was downgraded
from low to very low due to likely selection bias (non-randomised design) and confounding by study site (only one control site included,
results likely to be influenced by site-specific factors).
5Cohen 2015: Compared to an access rate of 19 percent in the control group, subsidies of 80 percent or more increased the likelihood
that a malaria-like illness is treated with an ACT by 16 to 23 percentage points (i.e. 85 to 118 percent increase). However, subsidies
were associated with overtreatment of malaria: only 56 percent of patients taking ACTs from the drug shop tested for malaria under the
92 percent subsidy.
6Total number of children surveyed at follow up at 12 months in Kangwana 2011. Data were collected on 2,749 children at baseline.
7Based on Kangwana 2011. The second publication Kangwana 2013 reported an absolute increase of 31.7% (22.0% to 41.3%).
8Based on Sabot 2009. Drug shops in population centres were more likely to stock ACTs than those in more remote areas (P <0.001).
9Downgraded from low to very low certainty evidence due to high likelihood of selection bias (non-randomised design) and confounding
by study site (only one control site included; results likely to be influenced by site-specific (contextual) factors).
10Based on Kangwana 2011 baseline values. ACT treatment course: six tablets (children aged 3-35 months) and 12 tablets (children
aged 36-59 months).
11Based on Kangwana 2011 follow-up (intervention site) data. 95.3% (SD 5.9%) of caregivers in the intervention arm at follow-up who
bought Tibamal said they purchased it at the recommended retail price of US$ 0.25. Of the eight not paying this price, three paid less
than US$ 0.25 and five paid between US$ 0.31 and 1.23.
12Kangwana 2013: In the mystery-shopper survey, at baseline there were only two doses of artemether-lumefantrine sold, at a cost of
US$ 2.46 and 2.22. At follow-up, the 12 tab Tibamal was sold at a median price of US$ 0.25 (IQR 20-20), which was the recommended
retail price. Of those not paying the recommended price, two paid US$ 0.37, another two paid US$ 0.49 because of buying two packs of
the six tab to meet the required dose, and one paid US$ 0.74.
13Talisuna 2012: “Maximum recommended retail price was within 10% of the recommended ACT price”. The recommended retail price
for an adult course of treatment - US$ 0.47 - was not adhered to (the median price at the endline survey was US$ 1.96).
14Sabot 2009: Children: the mean price paid for ACTs (US$ 0.19) was less than for both sulphadoxine-pyrimethamine (US$ 0.51, P =
0.001) and amodiaquine (US$ 0.86, P <0.001); the price paid for ACTs did not vary by socioeconomic status or geographical location
across all age groups; All age groups: the mean price for ACTs (US$ 0.58) did not differ from the price of sulphadoxine-pyrimethamine
(US$ 0.67), but was higher than for amodiaquine (US$ 0.48, P <0.001).
15Based on baseline data from Kangwana 2011 and Kangwana 2013.
16Sabot 2009 reported a market share of 8.9% (-0.5% to 18.2%) for children under 5 years of age, and 35.3% (29.8% to 40.7%) for
patients ≥ 16 years. Children under 5 years of age: purchases of sulphadoxine-pyrimethamine in the intervention districts decreased
from 7.0% to 4.0% and remained the same at 9.0% in the control district. Purchases of amodiaquine in the intervention districts declined
from 91.0% to 36.0%, and from 91.0% to 36.0% in the control district.
17Talisuna 2012: All age groups: market share for ACTs in the intervention group was 43% at baseline and 69% at follow-up (control
data not reported).
18Based on Kangwana 2011 baseline data.
19Talisuna 2012: At follow-up, use of quinine was 44% in the control group and 37% in the intervention group (odds ratio 0.76, 95%
confidence interval 0.54 to 1.08; no baseline data were reported).
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B A C K G R O U N D
Malaria is a major cause of ill health and death in Africa (WHO
2012). Uncomplicated Plasmodium falciparummalaria is the com-
monest form of the disease and accounts for most of the malaria
cases and deaths (WHO 2012). The World Health Organiza-
tion (WHO) recommends artemisinin-based combination ther-
apy (ACT) for the treatment of uncomplicated malaria (WHO
2012). These drugs are highly effective and have the potential to
reduce the development of antimalarial resistance. Unfortunately,
despite theWHO’s recommendation and substantial donor fund-
ing, only one in five antimalarial drugs used in malaria treatment
in malaria-endemic countries are ACTs (WHO 2009). Reasons
for the low use include high prices of ACTs in the retail sector
(drug shops and pharmacies) where most people seek treatment
for fever or suspected malaria (Patouillard 2010; Talisuna 2009).
The price of ACTs is typically more than 10 times the price of
older, less effective antimalarial drugs such as amodiaquine (AQ)
and sulphadoxine-pyrimethamine (SP) in the retail sector (Morris
2014).
Description of the intervention
From 2010 to 2012, the Global Fund established and operated a
new global subsidy programme, termed the Affordable Medicines
Facility-malaria (AMFm), funded by three donors (UNITAID,
the UK government and the Bill & Melinda Gates Foundation).
The programme operated in seven sub-Saharan African coun-
tries (Ghana, Kenya, Madagascar, Niger, Nigeria, mainland Tan-
zania and Zanzibar and Uganda). In November 2012, the Global
Fund board decided to change the way in which the ACT subsidy
scheme operated. Instead of being a ’stand alone’ initiative at the
Global Fund, the subsidy programme was incorporated into the
Global Fund’s core grantmanagement and financial processes. The
AMFm was renamed as the Private Sector Co-payment Mecha-
nism. As of mid-2014, Ghana, Madagascar and Tanzania had in-
tegrated the Private Sector Co-payment Mechanism into existing
Global Fund grants.
The aim of the AMFm subsidy is to reduce ACT retail prices to
a level similar to older, less effective antimalarial drugs in order
to increase demand and access for ACTs and displace artemisinin
monotherapy and other sub-standard malaria treatments from
the market, particularly among populations most vulnerable to
malaria (children under five years of age and poor rural popu-
lations). Under the AMFm, ’first-line buyers’ in the retail sector
(those who buy ACTs directly from the manufacturer) pay about
US$ 0.05 for a course of ACT rather thanUS$ 5.00 (the price paid
before the AMFm; RBM 2007). The public sector can also pur-
chase donor-subsidised ACTs, which may in turn broaden pub-
lic sector ACT access. The subsidy programme is combined with
supporting interventions (such as retail outlet provider training,
community awareness and mass media campaigns) to facilitate ef-
fective delivery and appropriate use of ACTs.
How the intervention might work
The AMFm subsidy programme is designed to increase access
to ACTs in the retail and public sector by subsidising the prices
of ACTs at the manufacturer level (Arrow 2004; Laxminarayan
2009). The programme aims to lower consumer prices of ACTs,
compared to older and less effective antimalarial drugs, available
through the retail sector via two mechanisms: (1) negotiating with
manufacturers of ACTs to reduce ACT prices; and (2) co-paying
a proportion (about 90%) of the reduced ACT price directly to
participating manufacturers, hence further lowering prices to el-
igible wholesalers of ACTs (Global Fund; Laxminarayan 2009).
The wholesalers thus pay a lower price for ACTs and prices fall all
along the supply chain, increasing affordability for the final con-
sumer, while at the same time undercutting the price of resistance-
inducing artemisinin monotherapy and competing with the prices
for chloroquine and SP.
The pre-specified benchmarks of success of the AMFm pilot by
the AMFm included: an increase in ACT use of 10 to 15 percent-
age points; increase in ACT availability of 20 percentage points;
increase in ACT market share of 10 to 15 percentage points; and
quality-assured ACT price less than 300% of the dominant non-
quality-assured ACTs (chloroquine or SP; Table 1). The AMFm
process is illustrated in Figure 1. In Figure 2 we provide a logic
framework for this review, showing the theory of impact of the
subsidies on malaria burden, potential influences on these steps
and the outcomes that can be measured to evaluate the subsidy
programmes.
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Figure 1. Illustrative example of the AMFm process
Figure 2. Logic framework for evaluating AMFm programme
Why it is important to do this review
ACT subsidy programmes are expensive. The initial costs of the
AMFm pilot that ran from 2010 to 2012 were estimated at US$
343 million: US$ 216 million for the subsidy and US$ 127 mil-
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lion for the supportive interventions (Global Fund). It is therefore
important to ensure that such programmes lead to intended out-
comes: lower ACT prices; increased ACT availability and usage;
crowding-out of older, less effective malaria drugs; and an end to
themarketing of artemisininmonotherapy (suchmarketingmight
increase the development of Plasmodium falciparum resistance,
rendering ACTs ineffective; Perkins 2008). It is also important to
make sure these subsidies do not have unintended consequences
(such as inappropriate use of ACTs among patients with non-
malarial fevers leading to drug wastage and delay in care-seeking
for appropriate treatment).
O B J E C T I V E S
To assess the effect of programmes that include ACT price subsi-
dies for private retailers on ACT use, availability, price and market
share.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies that assessed the effect of retail sector ACT price subsidies
using the following designs were eligible for inclusion (Appendix
1).
• Randomised trials.
• Non-randomised trials.
• Controlled before-after studies.
• Interrupted-time-series studies (with a clearly defined point
in time when the subsidy occurred, and at least three data points
before and three after the subsidy intervention).
Types of participants
Studies involving the following groups of patients and units or
channels of delivery of subsidised ACTs were eligible for inclusion.
• Consumers of retail sector subsidised ACTs (patients
seeking treatment for fever or malaria; both children and adults).
• Private retailers of subsidised ACTs (pharmacies, franchised
clinics, drug shops, general stores).
Types of interventions
Intervention
Studies assessing the effect of retail sector ACTprice subsidies were
eligible for inclusion.
• Retail sector ACT subsidy programmes (both for-profit and
not-for-profit retail sectors).
• Retail sector ACT subsidy programmes with supportive
interventions (e.g. retail outlet provider training, community
awareness and mass media campaigns).
Comparisons
• Alternative ACT financing mechanisms aiming to achieve
similar goals as retail sector ACT price subsidies (such as the
generic Global Fund financing mechanism aiming to expand
ACT availability in public health care facilities).
• Public sector interventions to increase ACT availability
funded by the United States President’s Malaria Initiative (PMI)
(http://www.pmi.gov/).
• Usual ACT delivery mechanisms (non-subsidised ACT
interventions).
Types of outcome measures
Primary outcomes
ACT use (defined as the percentage of patients with fever/con-
firmed malaria who received an ACT on the day that the fever
started or on the following day; Global Fund).
Secondary outcomes
• ACT availability (proportion of all facilities stocking ACTs
among outlets with any antimalarials in stock).
• ACT price (cost to patients of a full child or adult course of
ACTs).
• ACT market share (total volume of ACTs sold or
distributed as a proportion of the total volume of all
antimalarials sold or distributed via outlets).
• Use of older antimalarial drugs (AQ, chloroquine,
artemisinin monotherapy, SP).
• Adverse effects (such as the number of people receiving
ACTs who do not have malaria).
All studies with eligible designs, participants and interventions
were considered for inclusion irrespective of whether only the
above outcome measures were reported.
Search methods for identification of studies
Electronic searches
We aimed to identify eligible published and unpublished studies.
We searched the following databases and grey literature sources in
February, 2015.
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• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 1, The Cochrane Library) including
The Cochrane Effective Practice and Organisation of Care
(EPOC) Group Specialised Register.
• MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE Daily, MEDLINE and OLDMEDLINE, 1946 to
Present (OvidSP).
• Embase 1980 to 2015 Week 07 (OvidSP).
• CINAHL 1980 to present (EbscoHost).
• Regional Indexes (Global Health Library, WHO).
• LILACS (Global Health Library, WHO).
• Science Citation Index and Social Sciences Citation Index
(ISI Web of Science).
• EconLit 1969 to current (ProQuest).
• Global Health 1973 to 2015 Week 07 (OvidSP).
• Health Management (ProQuest; searched 27/11/2013
because we no longer have access to this database).
The searches were done without any language, date or publication
status restrictions. See Appendix 2 for all search strategies.
Searching other resources
Grey literature
• The Grey Literature Report from The New York Academy
of Medicine Library (http://www.greylit.org/; searched 04/11/
2013).
• Websites of the following institutions: the Global Fund, the
Roll Back Malaria partnership, Malaria Consortium, Medicines
for Malaria Venture, UNITAID, the Clinton Health Access
Initiative, PMI, World Bank (Booster Program for Malaria
Control in Africa), WHO Global Malaria Program, the United
Nations Children’s Fund (UNICEF), Drugs for Neglected
Diseases Initiative, Centre de Recherche pour le Développement
Humain, ACTwatch, Bill & Melinda Gates Foundation, UK
Department for International Development, Management
Sciences for Health Sustainable Drug Sellers Initiative, Oxfam
International and Center for Health Market Innovations
(searched 04/11/2013).
Trial registries
• WHO International Clinical Trials Registry Platform
(ICTRP; http://www.who.int/ictrp/en/; searched 04/11/2013).
• ClinicalTrials.gov, US National Institutes of Health (http://
clinicaltrials.gov/; searched 04/11/2013).
Additional resources
We also:
• hand searched relevant conference proceedings (e.g.
Multilateral Initiative on Malaria; searched 04/11/2013);
• hand searched reference lists of relevant articles (technical
reports, reviews; searched 04/11/2013);
• contacted authors of relevant articles regarding any further
published or unpublished work; and
• conducted cited reference searches for all included studies
in ISI Web of Knowledge (searched 19/02/2015).
Data collection and analysis
Selection of studies
Two review authors (NO, PG) independently screened titles, ab-
stracts and full texts of identified articles and applied the pre-spec-
ified study eligibility criteria to select studies. GY reviewed all arti-
cles selected for inclusion. We resolved any disagreements by dis-
cussion. We documented the number of articles screened, assessed
for eligibility and selected for inclusion in a PRISMA flow diagram
(Figure 3; Moher 2009). Studies initially considered eligible but
eventually excluded together with the reasons for exclusions are
presented in the Characteristics of excluded studies.
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Figure 3. Results of the literature search and studies selected
Data extraction and management
Two review authors (NO, PG) independently extracted outcome
data at baseline and endline. We also extracted data on study
settings (coverage), participants (patient age groups), retail out-
lets, interventions (level of price subsidy and duration of subsidy
programme), ACT supply (distribution) mechanisms and nature
of supportive interventions (Characteristics of included studies;
Table 2). Data were entered into a pilot-tested data extraction
form. We resolved any disagreements by discussion.
Assessment of risk of bias in included studies
Two review authors (NO, PG) independently assessed the risk of
bias in the included studies using the Cochrane EPOC ’Risk of
bias’ tool (EPOC 2014). Quality domains assessed included: al-
location sequence generation, allocation concealment, similarity
of baseline characteristics and outcome measurements, blinding
(personnel and outcome assessors), handling of incomplete out-
come data, protection against contamination, completeness of fol-
low-up and reporting of outcomes. We also assessed the following
additional cluster-specific sources of bias: recruitment bias, loss
of clusters, incorrect analysis and comparability with individually
randomised trials (Higgins 2011). Findings were classified into
three categories: low (low risk of bias for key quality domains, i.e.
allocation sequence generation and concealment), high (high risk
of bias for one or more of the key domains) and unclear (unclear
risk of bias for one or more key domains). We resolved any dis-
agreements by discussion.
We did not exclude studies on the basis of their risk of bias rat-
ings; rather, we used these findings to help us better understand
weaknesses in the identified evidence. We took into account the
11Subsidising artemisinin-based combination therapy in the private retail sector (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
risk of bias ratings when synthesising and interpreting results. We
report on the results of risk of bias assessment in the ‘Risk of bias’
tables and graphs (Figure 4; Figure 5).
Figure 4. Review authors’ judgements about each risk of bias item for each included study
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Figure 5. Review authors’ judgements about each risk of bias item presented as percentages across all
included studies
Measures of treatment effect
We have reported measures of subsidy effects as reported in the
primary studies. We have presented absolute estimates of effects
(percentage point differences, range and median effect sizes) with
95% confidence intervals (CIs) where estimable. For example, for
the outcome of ACT use, we reported percentage changes in con-
trol and intervention sites frombaselines and the absolute percent-
age point difference (cluster-adjusted) between the changes (i.e.
’difference-in-difference’ estimates; Table 3).
Unit of analysis issues
We assessed whether appropriate analysis was conducted to adjust
for clustering in estimating precision of effects in cluster trials
(Higgins 2011).
Dealing with missing data
We contacted authors of primary studies where relevant data were
missing or where we required further clarification on the reported
data. Where data were not available from the authors, we reported
the data as missing; we did not impute or extrapolate values.
Assessment of heterogeneity
We did not assess inconsistency between the results of individual
studies using statistical methods; differences in studies precluded
meta-analysis. We documented factors that could modify subsidy
effects (such as programme coverage, level of price subsidy, ACT
supply mechanism and nature of supportive interventions) in ac-
cordance with the established guidance for evaluating complex in-
terventions (Shepperd 2009; Table 2).
Assessment of reporting biases
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results (Sterne
2011). Reporting biases comprise publication bias, time lag bias,
multiple (duplicate) publication bias, location bias, citation bias,
language bias and outcome reporting bias. We assessed potential
selective reporting of outcomes as one component of risk of bias
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assessment (we focused on the completeness of reporting of pre-
specified outcomes). We did not create funnel plots as planned
because of insufficient data (only four studies were included in the
review) (Sterne 2011).
Data synthesis
The included studies utilised varied study designs (randomised
cluster and non-randomised cluster trials), enrolled diverse pop-
ulations (children and adults) and used different effect measures.
We therefore did not combine results using statistical methods.
We have described individual study results in the ’Effects of
interventions’ section.
’Summary of findings’ table and assessing the certainty of
evidence
We assessed the overall confidence in estimate of effect (certainty
of evidence) for each outcome using GRADE (Guyatt 2008). This
system classifies the certainty of evidence (defined as ‘the extent to
which one can be confident that an estimate of effect or association
is correct’) into four categories: very low, low, moderate or high.
Data from randomised trials start at high quality while data from
observational studies start at low quality. Quality of evidence from
randomised trials can be downgraded in consideration of five fac-
tors: risk of bias or study limitations, directness, consistency of re-
sults, precision and publication bias. Similarly, quality of evidence
from observational studies can be upgraded in consideration of
three factors: magnitude of effect estimate, dose-response gradient
and influence of residual plausible confounding.
Two review authors (NO, PG) independently assessed the cer-
tainty of evidence; we resolved disagreements by discussion. We
did not assess the certainty of evidence for outcomes where there
was insufficient data to permit reliable certainty rating. We did
not exclude studies on the basis of GRADE ratings; we took into
account the certainty of evidence when interpreting results.
We used GRADEpro software (GRADEpro 2015) to create ‘Sum-
mary of findings’ (SoF) tables for two comparisons: (1) ‘retail sec-
tor ACT subsidies combined with supportive interventions ver-
sus no subsidies’ (Summary of findings for the main comparison);
and (2) ’ACT subsidy vouchers versus no subsidies’ (Summary of
findings 2). We included all the pre-specified outcomes in SoF
table 1 and ACT access (defined as ’the share of illness episodes
treated with ACTs’) and targeting (defined as ’the share of ACT-
takers who are malaria positive’) in SoF table 2. We prioritised
findings from randomised trials (data from non-randomised trials
were incorporated as footnotes).
Subgroup analysis and investigation of heterogeneity
We intended to perform subgroup analysis to investigate potential
variation in subsidy effects by study design, nature of supportive
interventions, socioeconomic status and scale of coverage of subsi-
dies (sub-national versus national programmes). However, we did
not perform any of the planned analyses because there was insuf-
ficient data to permit reliable analysis.
Sensitivity analysis
We intended to conduct sensitivity analysis to assess the impact of
study quality on results (for example, whether effect estimates are
robust to changes in study risk of bias). We did not perform this
analysis as no meta-analysis was done.
R E S U L T S
Description of studies
Results of the search
We identified a total of 1705 articles from both the electronic
and supplementary searches. We excluded 1684 articles following
a review of the titles and abstracts. We retrieved the full texts of
21 articles for detailed eligibility assessment. We excluded 16 of
the articles because of ineligible study designs. No ongoing studies
were identified. Overall, four studies (five articles) fulfilled the re-
view inclusion criteria (Cohen 2015; Kangwana 2011; Kangwana
2013; Talisuna 2012; Sabot 2009; Figure 3).
Included studies
We included four studies (five articles; Characteristics of included
studies; Table 2)
Two studies (three articles) were cluster-randomised trials (Cohen
2015; Kangwana 2011; Kangwana 2013). The remaining studies
were non-randomised cluster trials (Sabot 2009; Talisuna 2012).
The studies were conducted in rural districts in Kenya (Cohen
2015; Kangwana 2011; Kangwana 2013), Uganda (Talisuna
2012) and Tanzania (Sabot 2009). One trial enrolled children
under five years of age (Kangwana 2011; Kangwana 2013); both
adults and children were studied in the other trials. One trial
(Kangwana 2011; Kangwana 2013) reported adequate power
(80%) for primary outcomes. Study power was not reported in
the other three studies.
ACT price subsidies were accompanied with supportive interven-
tions (including retail outlet provider training and community
awareness campaigns lasting less than a year) in all except one
study (Cohen 2015). The subsidy level was 95% in two studies
(Kangwana 2011; Kangwana 2013; Talisuna 2012), 80% to 92%
inone study (Cohen 2015) and90% in the remaining study (Sabot
2009). Post-intervention data collection periods were varied: 4
months (Cohen 2015), 12 months (Kangwana 2011; Kangwana
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2013; Sabot 2009) and 20 months (Talisuna 2012). Retail outlets
comprised specialised and general drug stores in all the studies.
Private clinics were included in one study (Talisuna 2012).
ACT supply and distribution chains were varied: a third party
procured and delivered ACTs directly to trained outlets from
which shopkeepers purchased the treatment at a wholesale price
in two trials (Kangwana 2011; Kangwana 2013; Talisuna 2012).
In one trial the project managers procured the ACTs directly from
the manufacturing drug company (Novartis) and sold them to
a wholesaler; drug shops purchased the ACTs from the whole-
saler (Sabot 2009). Households were provided with vouchers to
purchase subsidised ACTs from retail outlets in one trial (Cohen
2015).
Randomised cluster trials
Kangwana 2011 evaluated the impact of retail sector ACT
(artemether-lumefantrine; AL) subsidies in febrile children aged
3 to 59 months in Kenya. Nine areas were randomly allocated
to the intervention arm (ACT subsidy plus supportive interven-
tions, retail provider training and communication awareness ac-
tivities) and nine to the control arm, with a buffer zone of two
areas between selected areas. Subsidised AL was provided to retail
outlets from November 2008. Cross-sectional household surveys
were conducted before (July to August 2008) and after (July to Au-
gust 2009) the delivery of the intervention. The primary outcome
was the proportion of children reporting fever in the previous two
weeks who started treatment with AL on the same day as fever
onset or the following day. Secondary outcomes were adequacy
of AL doses obtained and consumed and the price paid per pack.
Data were collected on 2749 children in the target age group at
baseline and 2662 at one year follow-up.
Kangwana 2013 evaluated the impact of retail sector ACT subsi-
dies using provider and mystery-shopper survey data collected as
part of the randomised trial described above (Kangwana 2011).
Data were collected at baseline (July to August 2008) and fol-
low-up (July to August 2009) using provider and mystery shop-
per cross-sectional surveys. The mystery shopper survey assessed
patient-provider interactions and aimed to provide data on ac-
tual rather than self-reported provider practice. Outcomes assessed
included retail sector ACT availability, provider knowledge and
provider dispensing practices. A total of 468 outlets were assessed
at baseline and 639 at follow-up in the provider survey. 499 out-
lets were assessed at baseline and 653 at follow-up in the mystery
shopper survey.
Cohen 2015 studied the impact of ACT vouchers in three rural
districts in Kenya. Four drug shops (in four market centres) were
selected and all households in the catchment area (within a 4 km
radius) of these shops were sampled. Households were randomly
assigned to one of three groups: (1) ’No subsidy’ group (received
vouchers to purchase full price ACTs at the pre-AMFm retail
price of Kenya shillings 500 (approximately US$ 6.25 in 2009));
(2) ’ACT subsidy only’ group (received vouchers for ACT subsi-
dies of between 80% and 92%); (3) ’ACT plus rapid diagnostic
test (RDT) subsidy’ group (received vouchers for both subsidised
ACTs and RDTs. Two vouchers for ACTs (AL) and two vouchers
for RDTs (where applicable) were distributed to each household
following a baseline survey; 2789 (95%) out of the 2928 house-
holds sampled consented to the baseline survey. The trial was con-
ducted betweenMay and December 2009 (the endline survey was
administered about four months after the vouchers had been dis-
tributed). We only extracted data on ACT access and targeting in
the ’ACT subsidy’ only and ’No subsidy’ group. ACT access was
defined as ’the share of illness episodes treated with ACTs’. ACT
targeting was defined as ’the share of ACT-takers who are malaria
positive’.
Non-randomised cluster trials
Sabot 2009 assessed the impact of AMFm in three rural districts
in Tanzania. Since two of the selected districts were adjacent, ran-
domisation was limited so that one of the adjacent districts served
as the control. The selected districts were randomly assigned to
receive ACT subsidy, ACT subsidy plus suggested retail price or
no ACT subsidy (control). The intervention was implemented in
2007. Data were collected at baseline and during intervention us-
ing interviews with drug shop customers, retail audits, mystery
shoppers and audits of public and non-governmental facilities.
Most consumers interviewed in all districts were from the two least
poor socioeconomic status quintiles (59% and 68%, respectively).
A range of behaviour change communication (local radio adver-
tisements and wall paintings) highlighting the importance of us-
ing ACTs and their availability in private shops was conducted by
Population Services International. Outcomes assessed were ACT
uptake, availability and price. A total of 216 drug shops (duka la
dawa baridi) were studied. The report focuses on data collected
between August 2007 and August 2008.
Talisuna 2012 evaluated the impact of retail sector ACT sub-
sidies in Uganda. The pilot was implemented in 2008 and in-
volved four intervention districts (purposefully selected to receive
branded subsidised ACTs) and one control district. Supportive
interventions included communication and training activities to
improve awareness of the availability of subsidised ACTs and cor-
rect dispensing and use of ACTs. Outcomes assessed were ACT
uptake, availability, price, purchase within 24 hours of symptom
onset and market share. Reported data comprise 1162 interviews
at baseline (September 2008) and 5181 interviews at endline (May
2010) from 783 outlets.
Excluded studies
We excluded 16 studies from the analysis because the study de-
signs did not meet our inclusion criteria (uncontrolled pilots, pre-
post surveys or qualitative assessments; Characteristics of excluded
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studies). Some of the studies excluded were large country evalua-
tions without control sites where the observed effects could be true
effects or could be secular and not due to the subsidy intervention
(Tougher 2012; Table 4). Details of some of the excluded studies
are described below.
Tougher 2012 assessed the effect of AMFm in seven countries
(Ghana, Kenya, Madagascar, Niger, Uganda, Nigeria and Tanza-
nia (including Zanzibar)). Nationally representative baseline and
endpoint surveys of public and private sector outlets that stock
antimalarial treatments were conducted in each of the seven coun-
tries (eight national-level pilots). Clusterswere selected usingprob-
ability proportional to size sampling; independent samples were
drawn at baseline and endpoint (a full census of outlets was done
in Zanzibar because of the small population size). Outcomes as-
sessed were ACT price, availability and market share. These out-
comes were assessed against pre-specified success benchmarks after
one year of AMFm implementation (Table 1). Data on the imple-
mentation process and contextual factors (e.g. supportive inter-
ventions, mechanisms of distribution of co-paid ACTs) were col-
lected through key informant interviews and document reviews.
Although this study provides important evidence on AMFm ef-
fectiveness at a national scale we did not include it because it used
a before-after design with no comparator sites. The lack of control
sites limits the degree to which observed effects can be attributed
to AMFm (findings may have been influenced by secular trends
in measured outcomes and concurrent malaria interventions).
We identified six national programmes to scale-up subsidised
ACTs in Cameroon, Senegal, Cambodia, DRC, Madagascar and
Rwanda (Table 4). Although the programmes report results in-
dicative of the kind of effect ACT subsidies can have under ’real
world’ conditions, we did not include them because they lacked
comparison groups. In addition baseline data were not available
for five of the national programmes (such data were only available
for Rwanda’s national programme).
Risk of bias in included studies
Wehave presentedfindings on risk of bias assessment using ’Risk of
bias’ tables and graphs (Characteristics of included studies; Figure
4; Figure 5). The overall risk of bias was low in two trials (Cohen
2015; Kangwana 2011; Kangwana 2013); it was high in the other
two (Sabot 2009; Talisuna 2012).
Random sequence generation and allocation concealment were
judged to be adequate (indicating low risk of selection bias) in
two trials (Cohen 2015; Kangwana 2011; Kangwana 2013); in the
other two they were inadequate (high risk of selection bias). Base-
line outcome measures and characteristics between study groups
were comparable in all studies. Blinding of personnel (retail outlet
providers) and data collectors (interviewers) was not possible in
three studies given the public awareness campaigns around sub-
sidised ACTs (Kangwana 2011; Kangwana 2013; Sabot 2009;
Talisuna 2012). Performance and detection biases due to lack of
blinding were considered low in all studies. The risk of contamina-
tion (potential leakage of subsidy intervention into control sites)
was low in all except one trial (Sabot 2009), where it was high.
None of the trials were at risk of attrition bias or selective outcome
reporting. No additional source of bias was present for the cluster-
specific domains except for possible recruitment bias in one trial
(Sabot 2009).
Effects of interventions
See: Summary of findings for the main comparison ACT
subsidies combined with supportive interventions versus no
subsidies; Summary of findings 2 ACT price vouchers versus no
subsidies
We have presented effect estimates and certainty of evidence for
each outcome in GRADE tables (Summary of findings for the
main comparison; Summary of findings 2; Appendix 3; Appendix
4).We did not report the certainty of evidence for outcomes where
there was insufficient data for GRADE assessment.
Comparison 1: ACT subsidies combined with supportive
interventions versus no subsidies
Three studies were included in this comparison (Kangwana 2011;
Kangwana 2013; Sabot 2009; Talisuna 2012).
Primary outcome
Two studies reported data on ACT use (Kangwana 2011; Talisuna
2012; Table 3). In the first study (Kangwana 2011), ACT subsidy
programmes increased ACT usage in children under five years of
age by 25 percentage points (95% CI 14.1 to 35.9 percentage
points; high certainty evidence). This suggests that in practice,
among febrile children under five years of age with an ACT usage
rate of 5% without a subsidy, subsidy programmes would increase
usage by between 19% and 41%. In the second study (Talisuna
2012), ACT subsidy programmes resulted in a ten-fold increase
(95% CI 5.0 to 18.9) in ACT usage in children under five years
of age and a six-fold increase (95% CI 4.2 to 8.4) in ACT usage
in all age groups (very low certainty evidence).
Secondary outcomes
Two studies reported data on ACT availability (Kangwana 2011;
Kangwana 2013; Sabot 2009; Table 5). In the first study (
Kangwana 2011; Kangwana 2013), ACT subsidy programmes in-
creased the percentage of retail outlets stocking ACTs for children
under five years of age by 31.9 percentage points (95% CI 26.3
to 37.5 percentage points; high certainty evidence). In the second
study (Sabot 2009), ACT subsidy programmes increased the per-
centage of retail outlets stocking ACTs for patients of any age by
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72.2 percentage points (95% CI 65.0 to 79.3 percentage points;
very low quality evidence).
Three studies reported data on ACT price outcomes (Kangwana
2011; Kangwana 2013; Sabot 2009; Talisuna 2012; Table 6). In
the first study (Kangwana 2011), ACT subsidy programmes de-
creased the median price for ACT prescribed for children under
five years of age by US$ 0.84 (median cost per ACT course with-
out subsidy: US$ 1.08 versus with subsidy: US$ 0.24; high cer-
tainty evidence). In the second study (Talisuna 2012), “the max-
imum recommended retail price was within 10% of the recom-
mended ACT price”. In addition, the recommended retail price
for an adult course of treatment (US$ 0.47) was not adhered to
(the median price at the endline survey was US$ 1.96). In the
third study (Sabot 2009), the mean price paid for paediatric ACTs
(US$ 0.19) was less than for both SP (US$ 0.51, P = 0.001) and
AQ (US$ 0.86, P < 0.001). The mean price for ACTs for any age
(US$ 0.58) did not differ from the price of SP (US$ 0.67), but
was higher than the price for AQ (US$ 0.48, P < 0.001).
Three studies assessed ACT market share outcomes (Kangwana
2011; Kangwana 2013; Sabot 2009; Talisuna 2012; Table 7). In
the first study (Kangwana 2011; Kangwana 2013), ACT subsidy
programmes increased market share of ACTs among children un-
der five years of age by between 23.6 and 63.0 percentage points
(high certainty evidence). In the second study (Talisuna 2012), the
market share for ACTs for patients of any age in the intervention
group was 43% at baseline and 69% at follow-up (control data
not reported). In the third study (Sabot 2009), the market share
for ACTs for children under five years of age increased by 8.9% (-
0.5% to 18.2%), and 35.3% (29.8% to 40.7%) for patients aged
at least 16 years.
Two studies reported data on use of older antimalarials (Kangwana
2011; Talisuna 2012; Table 8). In the first study (Kangwana 2011),
ACT subsidy programmes decreased use of AQ and SP among
children under five years of age by 10.4 percentage points (95%
CI 3.9 to 16.9 percentage points; high certainty evidence). In the
second study (Talisuna 2012), at follow-up, use of quinine was
44% in the control group and 37% in the intervention group
(odds ratio 0.76, 95% CI 0.54 to 1.08; all age groups; no baseline
data were reported).
None of the three studies measured adverse effects of ACT subsidy
programmes.
Comparison 2: ACT vouchers versus no subsidies
One study assessed the effect of ACT vouchers to households
on ACT access and targeting, among other outcomes (Cohen
2015). Compared to an access rate of 19% in the control group,
subsidies of 80% or more increased the likelihood that a malaria-
like illness was treated with an ACT by 16 to 23 percentage points
(representing an 85% to 118% increase). However, subsidies were
associated with a high rate of over-treatment of malaria: only 56%
of patients taking ACTs from the drug shops tested positive for
malaria under the 92% subsidy. The two lower subsidy levels were
associated with much higher malaria positivity rates: “drug shop
ACT-takers were 18 to 19 percentage points more likely to be
malaria-positive under the 88 and 80 percent subsidies than under
the 92 percent subsidy” (high certainty evidence).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Effects of ACT price vouchers on ACT accessibility and targeting
Patient or population: Patients seeking treatment for suspected uncomplicated malaria
Settings: Three rural malaria endemic districts in Western Kenya
Intervention: ACT subsidy (ACT vouchers to households; 80% to 92% subsidy)
Comparison: No subsidy (households received vouchers to purchase unsubsidised ACTs at the pre-AMFm retail price)
Outcomes Effect Number of participants
(studies)
GRADE certainty of the
evidence
Comments
ACT access (percent-
age of illness episodes
treated with ACTs; all age
groups)
Follow-up: 4 months
Compared to an access
rate of 19% in the control
group, subsidies of 80%
or more increased the
likelihood that a malaria-
like illness is treated with
an ACT by 16 to 23 per-
centage points, that is,
85% to 118% increase
2,789 households
(1 study)
⊕⊕⊕⊕
High
Cohen 2015
ACT targeting (percent-
age of ACT takerswho are
malaria positive; all age
groups)
Follow-up: 4 months
Subsidies were associ-
ated with a high rate of
over-treatment of malaria
(only 56% of patients tak-
ing ACTs from the drug
shop tested positive for
malaria under the 92%
subsidy)
2,789 households
(1 study)
⊕⊕⊕⊕
High
Cohen 2015
ACT: artemisinin-based combination therapy; AMFm: Affordable Medicines Facility-malaria
About the certainty of the evidence (GRADE)∗
High: This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different† is low
Moderate: This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different† is
moderate
Low: This research provides some indication of the likely effect. However, the likelihood that it will be substantially different† is high
Very low: This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially
different† is very high
∗This is sometimes referred to as ‘ quality of evidence’ or ‘ confidence in the estimate’
†Substantially different = a large enough difference that it might affect a decision
D I S C U S S I O N
Summary of main results
This systematic review examined evidence from studies that eval-
uated the effect of subsidy programmes aimed at improving ac-
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cessibility and use of ACT for treatment of malaria. Four trials
(five publications) that included substantive subsidies for private
retailers were included in the review. All the studies were carried
out in three adjacent countries in East Africa (Kenya, Uganda and
Tanzania), and had accompanying interventions, including retail
outlet provider training, community awareness and mass media
campaigns.
The findings indicate that programmes that include substantive
price subsidies (90% or more) for private antimalarial drug retail-
ers improve use of ACTs (by 25 percentage points) among chil-
dren under five years of age with suspectedmalaria. In practice this
suggests that, among febrile children with an ACT usage rate of
5% without a subsidy, subsidy programmes would increase usage
by between 19% and 41%. The findings also indicate that sub-
sidy programmes improve ACT stocking in retail outlets (by 32
percentage points) and lower ACT prices (by US$ 0.84 per dose)
for children under five years of age with suspected malaria. The
impact on ACT stocking for patients of any age is unknown be-
cause the certainty of evidence was very low. Subsidy programmes
also improve ACT market share (by between 24 to 63 percentage
points) among patients of any age and reduce the use of older an-
timalarials (by 10 percentage points) among children under five
years of age.
The findings also show that retail-sector ACT subsidies using
vouchers lead to substantial increases in ACT access among peo-
ple seeking treatment for suspected malaria. However, these sub-
sidies also increase inappropriate use of ACTs (that is, increase the
proportion of people who receive ACTs but do not in fact have
malaria).
Overall completeness and applicability of
evidence
The data that were used in this review are from studies where
malaria was mostly diagnosed based on the presence of fever in
people seeking treatment for suspected malaria. The number of
patients with confirmed (parasite-diagnosed) malaria was unclear
in most of the studies; we therefore do not know whether subsidies
resulted in over-treatment of malaria, except in the study of ACT
vouchers where this was measured. None of the identified studies
assessed mortality or other clinical outcomes. Furthermore, the
studies did not examine patient adherence to subsidised ACTs.
Thus, whether the observed improvement in ACT usage would
translate into real health benefits remains uncertain. It is also un-
known whether the impact of subsidies would vary by scale of cov-
erage (sub-national vs. national subsidy programmes), ACT sup-
ply (distribution) mechanisms to retail outlets or socioeconomic
status (there were insufficient data to explore effects across these
subgroups).
All the included studies were conducted in rural communities in
low-income countries where malaria remains prevalent. Review
findings are mostly generalisable to similar settings. However, the
small scale nature of the subsidy programmes included in this re-
view, differences in the ACT supply mechanisms and retail sec-
tor distribution chains across settings may limit generalisability in
some areas. Zambia, for example, has a more expansive public sec-
tor distribution chain compared to the private sector (Patouillard
2010).
Decisions to incorporate retail sector ACT subsidies into national
malaria control programmes need to involve consideration of in-
dividual country contexts (which could include local malaria epi-
demiology, public sector to private sector antimalarial market ra-
tio, diagnostic and distributional capacity of retail outlets, access
to rapid malaria diagnostics and treatment seeking behaviours).
In addition malaria subsidy policies need to balance the benefits
of retail sector ACT subsidies and potential unintended adverse
effects (for example, delaying the formal treatment-seeking that is
needed for correct diagnosis and treatment of malaria and non-
malarial fevers; under-treatment of malaria (under-dosing); failing
to diagnose and treat co-morbid non-malarial fevers such as pneu-
monia; and over-treatment ofmalaria resulting from inappropriate
use of subsidised ACTs in individuals with non-malarial fevers).
Such use of ACTs may increase the likelihood of emergence of
artemisinin resistance.
Quality of the evidence
The randomised trials provided high quality evidence on subsidy
effects (Cohen 2015; Kangwana 2011; Kangwana 2013). The cer-
tainty of evidence for all outcomes reported in the three trials was
judged to be high (i.e. the research provides a very good indication
of the likely effect).
The findings from the other two studies were susceptible to bias
(Sabot 2009; Talisuna 2012). We downgraded the certainty of ev-
idence (for ACT stocking for patients of any age) in one study
because of high likelihood of selection bias (non-randomised eval-
uation) and possible confounding by study site (only one control
site included; results were likely to be influenced by site-specific
factors; Sabot 2009).
We excluded several studies because they used ineligible designs
prone to bias. The ideal designs to assess the effects of large scale
public health interventions such as ACT subsidy programmes are
cluster-randomised trials with comparable control sites. However,
such experimental designs are rarely feasible in practice. For ex-
ample, cluster randomisation of regions in the included studies
was limited by the need to use existing pharmaceutical retail dis-
tribution channels. Consequently, implementation of the subsidy
interventions could not be restricted to certain areas as predicted
by randomisation processes. Furthermore, identification of com-
parable control groups remains a challenge given inherent differ-
ences in contexts such as health systems arrangements in malaria-
endemic settings. This challenge was addressed in one included
study (Kangwana 2013) through documentation of the context
and processes of subsidy implementation (in line with the rec-
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ommendations for the evaluation of complex interventions; Craig
2008; Shepperd 2009).
Potential biases in the review process
We excludedmany potentially eligible studies because of ineligible
study designs. It is possible that some of these studies provide
useful information that might complement findings from the four
included studies. For example, positive effects observed in the
included studies were replicated in one excluded study (Tougher
2012). Consistent findings from different study designs across
varying malaria transmission and cultural contexts increase our
confidence that observed improvements in ACT use, availability,
prices and market share can be attributed to the studied subsidy
programmes.
We intended to include only randomised trials, non-randomised
trials, controlled before-after studies with at least two interven-
tion and two control sites and interrupted-time-series studies
(Appendix 1). These criteria were necessary to minimise possi-
ble confounding of subsidy effects by site-specific factors (such
as ACT supply chains, regulatory policies and retail provider be-
haviours). However, we made a post-hoc decision to include two
non-randomised cluster trials (Sabot 2009; Talisuna 2012) which
compared intervention sites to only one control site. We therefore
cannot rule out the possible influence of site-specific factors on ob-
served subsidy effects (hence the decision to downgrade certainty
of evidence in Sabot 2009). In addition, government regulatory
interventions to phase out monotherapy (AQ/SP) may have con-
tributed to the observed decline in the use of these drugs in Kenya
and Uganda (Kangwana 2011; Talisuna 2012). We also did not
assess effects on two outcomes as planned in our protocol: ’avail-
ability of alternative antimalarial drugs in all facilities, private and
public (including informal outlets)’ and ’prices of alternative anti-
malarial drugs (full adult or child courses)’; we used six outcomes
included in the ’Summary of findings’ tables.
Agreements and disagreements with other
studies or reviews
We identified one related review and one study of the impact of
ACT subsidy programmes (Morris 2014; Tougher 2012).
Morris 2014 assessed the impact of retail sector ACT subsidies on
ACT use. The review included 40 studies, comprising 10 exper-
imental subsidies in eight countries, non-AMFm programmatic
subsidies in nine countries and AMFm subsidies in eight pilots.
Reported findings were derived from four experimental subsidies,
three programmatic subsidies and five of the eight AMFm pi-
lot subsidies. ACT subsidies substantially increased use of ACTs
among patients with suspected malaria: each US$1 decrease in
price was linked to a 24 percentage point increase in the fraction
of suspected malaria cases purchasing ACTs. There were no dif-
ferences in ACT use among the poorest and richest groups, rural
versus urban populations or children versus adults. The authors
concluded that ACT price reductions can increase ACT use for
suspected malaria, even within poorer, more remote populations
that may be most at risk of malaria mortality.
Tougher 2012 assessed the effect of the AMFm in seven coun-
tries (Ghana, Kenya, Madagascar, Niger, Uganda, Nigeria and
Tanzania (including Zanzibar)). The study used a before-after de-
sign with no comparator sites (see Excluded studies for details
on study methods). The AMFm resulted in a large increase in
quality-assured ACT (QAACT) availability (by 25.8 to 51.9 per-
centage points) in all pilots except Niger and Madagascar, and a
large increase in ACT market share (by 15.9 to 40.3 percentage
points), driven mainly by changes in the private for-profit sector.
Median price for QAACTs per adult equivalent dose decreased
substantially in the private for-profit sector in six pilots; the de-
crease ranged from US$1.28 to $4.82. The market share of oral
artemisinin monotherapies decreased in Nigeria and Zanzibar, the
two pilots where it was more than 5% at baseline. The authors
concluded that subsidies combined with supporting interventions
can be effective in rapidly improving availability, price and market
share of QAACTs, particularly in the private for-profit sector.
We did not conduct a quality assessment (risk of bias) for the ev-
idence presented in the related review and study; these findings
should therefore be interpreted with caution. However, despite
differences in study designs, the conclusions in both studies are
consistent with the findings of our review: ACT subsidies com-
bined with supportive interventions increase ACT usage, avail-
ability and market share and lower ACT prices for people seeking
treatment for suspected malaria.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings of this review suggest that programmes that include
substantive price subsidies (90% or more) for ACTs for private
retailers combined with provider training and marketing improve
use and availability of ACTs and lower ACT prices for children
under five years of age with suspected malaria. This research has
also shown that subsidy programmes improve market share of
ACTs (volume of ACTs distributed as a proportion of total volume
of all antimalarials distributed via outlets) and reduce use of older,
less effective antimalarials for children. We could not draw any
conclusion on the impact on ACT stocking for patients of any age
because the certainty of evidence was very low.
Decisions to incorporate retail sector ACT subsidies into national
malaria control programmes need to involve consideration of indi-
vidual country contexts and weigh the benefits of subsidies against
potential unintended consequences (such as over-treatment of
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malaria resulting from inappropriate use of ACTs among patients
with non-malarial fevers). Efforts to scale-up retail sector ACT
subsidy programmes in malaria-endemic settings (for example, via
licensed community based pharmacies) should be complemented
with policies to strengthen health systems (for example, enhanced
malaria diagnostics using subsidised rapid diagnostic tests to im-
prove ACT targeting; improved antimalarial drug supply in the
public sector; in-service malaria case management training; and
routine monitoring and surveillance for safety and impact).
Implications for research
Thenumber of patientswith confirmed (blood-diagnosed)malaria
was unclear in most of the included studies. Thus, future stud-
ies should investigate options to better target subsidised ACTs to
patients who actually have malaria (for example, effectiveness of
retail sector ACT subsidies combined with subsidies for rapid di-
agnostic tests). Optimal targeting of subsidised ACTs would in-
crease the likelihood that non-malarial illness such as pneumo-
nia (the symptoms of which are often similar to those of malaria)
are promptly diagnosed, treated or referred. Such targeting would
also reduce the likelihood of emergence of artemisinin resistance.
These studies should ideally use cluster-randomised, interrupted-
time-series or plausibility designs (Victora 2004).
Future studies should also investigate pharmacovigilance and the
extent of under- and over-treatment of malaria resulting from in-
appropriate targeting of retail sector ACT subsidies. The cost-ef-
fectiveness and sustainability of subsidy programmes compared to
alternative financing mechanisms and other approaches to expand
access to subsidised malaria drugs (such as private retail sector-
public partnerships and community based strategies) also need to
be investigated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Sabot 2009
Methods Non-randomised controlled cluster trial
Participants Country: Tanzania
Setting (coverage): 2 intervention districts, 1 control district
Outlets: Small drug shops (duka la dawa baridi)
Age group: All age groups
Interventions Intervention: Subsidised ACT (AL)
Comparison: No ACT subsidy (control)
Supportive interventions: Behavior change communication (e.g. local radio advertise-
ments, wall paintings, themed cultural shows) emphasising the importance of using
ACTs and their availability in private shops
Outcomes ACT uptake, availability and price
Notes The project managers procured AL from the manufacturer, Novartis, and sold them to
a pharmaceutical wholesaler in Dar es Salaam at an average of US$ $0.11 per dose, 88%
below the price offered to public buyers
In one of the intervention districts (Kongwa), the suggested retail price intended to
inform consumers of the maximum amount they should pay was set at 300, 600, 900,
and 1200 Tanzanian shillings (0.25, 0.50. 0.75. and 1 USD respectively) for the four
weight packs respectively; no suggested retail price was included on drugs distributed to
Maswa in order to test its effect on price outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The selected districts were randomly
assigned to one of the three arms in the study
design: subsidy, subsidy plus suggested retail
price, and no subsidy (control). As two of the
qualified districts were adjacent, randomiza-
tion was limited so that one of the adjacent
districts served as the control”
Comment: Non-randomised design
Allocation concealment (selection bias) High risk Quote: “The selected districts were randomly
assigned to one of the three arms in the study
design: subsidy, subsidy plus suggested retail
price, and no subsidy (control). As two of the
qualified districts were adjacent, randomiza-
tion was limited so that one of the adjacent
districts served as the control”
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Sabot 2009 (Continued)
Comment: Non-randomised design
Baseline outcome measurements Low risk Comment: No important differences across
study groups on pre-specified subsidy out-
come measures
Baseline characteristics Low risk Quote: “The selected districts were among
the few roughly comparable across all indi-
cators, with high malaria transmission, large
numbers of private drug shops and, impor-
tantly, no malaria related trials (e.g. vaccines)
underway”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Blinding was not possible for
study personnel and ACT providers due to
the public information campaign around the
subsidised drugs in the intervention arm.
Lack of blindingwas, however, unlikely to in-
fluence results as the outcomes assessed were
objective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Blindingwas not possible for data
collectors due to the public information cam-
paign around the subsidised drugs in the in-
tervention arm. Lack of blinding was how-
ever unlikely to influence results as outcomes
assessed were objective
Contamination High risk Quote: “As two of the qualified districts were
adjacent, randomization was limited so that
one of the adjacent districts served as the con-
trol”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: The number of drug shops closed
or refusing to participate were 30 (13%) and
39 (15%) respectively
Selective reporting (reporting bias) Low risk Comment: Data on pre-specified outcomes
reported
Recruitment bias High risk Quote: “The selected districts were randomly
assigned to one of the three arms in the study
design: subsidy, subsidy plus suggested retail
price, and no subsidy (control). As two of the
qualified districts were adjacent, randomiza-
tion was limited so that one of the adjacent
districts served as the control”
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Sabot 2009 (Continued)
Loss of clusters Low risk Quote: “The total number of DLDB audited
increased from 200 in August 2007 to 216
in August 2008 due to the opening of new
shops, with 30 (13%) and 39 (15%) addi-
tional shops closed or refusing to participate
at these two time periods respectively.”
Incorrect analysis Low risk Quote: “To assess geographical variation
in outcomes, the competition level of all
DLDB was calculated using the fixed radius
approach...The competitive space of each
DLDB was defined as 1 kilometer and each
shopwas assigned to a competition index cat-
egory between 0 and 5 based on the number
of other DLDB within that radius.”
“A repeated measures multivariate regression
model was used to compare differences in
purchase price while controlling for poten-
tially confounding factors and adjusting for
clustering of multiple purchases in the same
shops.”
Comparability with individually ran-
domised trials
Low risk Comment: Included clusters comparable
Kangwana 2011
Methods Cluster-randomised controlled trial
Participants Country: Kenya
Setting (coverage): 3 districts (9 sublocations allocated to intervention, 9 sublocations
allocated to control)
Outlets: Retail outlets (specialised drug shops and general shops)
Age group: Children under 5
Interventions Intervention: Tibamal (subsidised ACT: AL) plus supportive interventions
Comparison: No subsidised ACT (control)
Supportive interventions: Training of retail outlet staff, job aids, community awareness
activities (e.g. workshops, posters and paintings on shops; these activities were designed
tomake the community aware of malaria, the availability of Tibamal, and the importance
of adherence to the medication)
Outcomes Primary outcome: proportion of children reporting fever in the past 2 weeks who started
treatment with AL on the day or following day of fever onset. Secondary outcomes:
adequacy of AL doses obtained and consumed and the price paid per pack
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Notes At the time of the study, AL had a retail price of around US$ 6.16 (500 Kenyan shillings)
compared with an average of around US$ 0.37 for common, older antimalarials such as
SP and AQ. The outlets were instructed to sell the packs at a retail price of US$ 0.25,
which was printed on the drug packaging, providing a 150% retailer mark-up (exceeding
that of AQ and SP, which generally had retail markups of 50% to 100%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: A random list of all eligible sublo-
cations was formulated per district in Microsoft
Excel. The first intervention sublocation was se-
lected from the top of the list. In order to reduce
the potential for contamination a “buffer zone”
was created where all sublocations located within
two sublocation boundaries of the selected sublo-
cation were removed from the list. The list was
reshuffled randomly and the first sublocation on
the new list allocated to the control arm
Allocation concealment (selection bias) Low risk Comment: The same procedure as for random
sequence generation (described above) was used;
intervention allocation could not have been seen
in advance
Baseline outcome measurements Low risk Comment: No important differences across study
groups on pre-specified subsidy outcome mea-
sures
Baseline characteristics Low risk Comment: Baseline characteristics of study
groups reported and comparable
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Blinding was not possible for shop-
keepers and communitymembers due to the pub-
lic information campaign around the subsidised
drugs in the intervention arm. Lack of blinding
was, however, unlikely to influence results as the
outcomes assessed were objective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Blinding was not possible for data col-
lectors due to the public information campaign
around the subsidised drugs in the intervention
arm. Lack of blinding was, however, unlikely to
influence results as outcomes assessed were objec-
tive
27Subsidising artemisinin-based combination therapy in the private retail sector (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Kangwana 2011 (Continued)
Contamination Low risk Quote: “No children in the control arm were
reported to have received Tibamal (subsidised
ACT) at follow-up. In addition, at follow-up 82%
of caregivers in the intervention arm had heard
of Tibamal, compared to only 7% in the control
arm.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: In the control arm, of 1,679 house-
holds interviewed at baseline, 152 were lost to fol-
low-up; in the intervention arm, Of 1,609 house-
holds interviewed, 114 were lost to follow-up
Selective reporting (reporting bias) Low risk Comment: Data on prespecified outcomes were
reported
Recruitment bias Low risk Quote: “A random list of all eligible sublocations
was formulated per district in Microsoft Excel.
The first intervention sublocation was selected
from the top of the list...The list was reshuffled
randomly and the first sublocation on the new list
allocated to the control arm.”
Loss of clusters Low risk Quote: “We completed interviews in 2,319
homesteads at baseline (3,288households), and2,
204 homesteads at follow-up (3,182 households)
.All randomised clusters included in the analysis.
”
Incorrect analysis Low risk Quote: “A separate analysis allowing for clustering
within homesteads was also conducted.”
Comparability with individually ran-
domised trials
Low risk Comment: Included clusters comparable
Talisuna 2012
Methods Non-randomised controlled cluster trial
Participants Country: Uganda
Setting (coverage): 4 intervention districts, 1 control district
Outlets: Drug shops (private drug shops, private clinics, pharmacies)
Age group: All age groups
Interventions Intervention: Subsidised ACT plus supportive interventions
Comparison: No ACT subsidy (control)
Supportive interventions: Communication activities to improve awareness of the impor-
tance and availability of ACTs, and training activities to ensure correct dispensing and
use of subsidised ACTs
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Outcomes ACT uptake, purchase of ACT within 24 hours of symptom onset and ACT price,
availability and market share
Notes There was better availability of ACT in the public sector in the control district because
of: (1) new interventions initiated targeting the community level distribution of ACTs
through the public sector; and (2) improvements in the procurement and distribution
system in the public sector, based on a push instead of a pull system for the lower level
health units
The maximum recommended retail price for the subsidised ACT ranged from 200
Ugandan shillings to 800 Ugandan shillings (US$ 0.10 to 0.40), depending on the target
age/doses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Four intervention districts were pur-
posefully selected to receive branded sub-
sidised medicines - ’ACT with a leaf ’, while
the fifth district acted as the control.”
Comment: Non-randomised design
Allocation concealment (selection bias) High risk Quote: “Four intervention districts were pur-
posefully selected to receive branded sub-
sidised medicines - ’ACT with a leaf ’, while
the fifth district acted as the control.”
Comment: Non-randomised design
Baseline outcome measurements Low risk Comment: No important differences across
study groups on pre-specified subsidy out-
come measures
Baseline characteristics Low risk Quote: “Some discordance was observed be-
tween the intervention and control districts
at baseline in terms of drug consumption
habits. Fortunately, the observed disparities
did not include the use of ACT. Generating
survey-adjusted outputs was intended to pro-
vide a more reasonable range of likely val-
ues that accounted for this prior to executing
tests of significance”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Blinding was not possible for
drug shop personnel due to the public in-
formation campaign around the subsidised
drugs in the intervention arm. Lack of blind-
ing was, however, unlikely to influence out-
comes as outcomes assessed were objective
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Talisuna 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Possible interviewer bias minimised
through a week long training to instil strict
processes for conducting interviews, and to
minimise deviation from the interview script.
It was unlikely that the lack of blinding could
influence outcomes as it was obligatory for
the interviewer to observe and record the de-
tails of the actual medicine purchased.”
Contamination Low risk Quote: “To limit leakage of the intervention
to the control area, the control and interven-
tion areas had two intervening buffer districts
(Bukedea and Kumi) or a lake between them.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “...the rate of refusal was generally
small (not exceeding 10%) and any effect due
to refusal probably did not impact signifi-
cantly on the outcome measures.”
Comment: Of the 5,643 observations col-
lected in the final evaluation survey, 5,181
observations resulting from visits to 783 out-
lets were included in the analysis
Selective reporting (reporting bias) Low risk Comment: Data on pre-specified outcomes
reported
Recruitment bias Low risk Quote: “Four intervention districts were pur-
posefully selected to receive branded sub-
sidised medicines - ’ACT with a leaf ’, while
the fifth district acted as the control.”
Loss of clusters Low risk Quote: “Following the baseline survey, [Con-
sortium for ACT Private Sector Subsidy] ini-
tiated the ACT subsidy for the intervention
districts and four subsequent rounds of mon-
itoring of cross-sectional surveyswere admin-
istered in the same manner as the baseline
survey, with the final round occurring during
the period 20 April - 11 May, 2010 (Base-
line: n=1,162; round 1: n=1044; round 2: n=
1794; round 3: n=1976 and final round 4: n=
5181). A minimum number of 5 interviews
per outlet were respected in the final survey
round, resulting in a significantly higher sam-
ple size.”
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Talisuna 2012 (Continued)
Incorrect analysis Low risk Quote: “Based on the data-collection meth-
ods, a survey-adjusted logistic regression
model was used. The outlets were treated
as the population sampling units within five
strata - the five pilot districts.”
Comparability with individually ran-
domised trials
Low risk Comment: Included clusters comparable
Kangwana 2013
Methods Cluster-randomised controlled trial
Participants Country: Kenya
Setting (coverage): 3 districts (9 sublocations allocated to intervention, 9 sublocations
allocated to control)
Outlets: Retail outlets (specialised drug shops and general shops)
Age group: Children under 5
Interventions Intervention: Tibamal (subsidised ACT: AL) plus supportive interventions
Comparison: No subsidised ACT (control)
Supportive interventions: Training of retail outlet staff, job aids, community awareness
activities (e.g. workshops, posters and paintings on shops; these activities were designed
tomake the community aware of malaria, the availability of Tibamal, and the importance
of adherence to the medication)
Outcomes ALuptake (provider behaviour), availability of older antimalarials, AL price, AL stocking,
provider knowledge, and provider dispensing practices. Generally, outlets that received
subsidised AL plus training and job aids performed better than those receiving one or
none of these intervention components
Notes At the time of the study, AL had a retail price of around US$ 6.16 (500 Kenyan shillings)
compared with an average of around US$ 0.37 for common, older antimalarials such as
SP and AQ. The outlets were instructed to sell the packs at a retail price of US$ 0.25,
which was printed on the drug packaging, providing a 150% retailer mark-up (exceeding
that of AQ and SP, which generally had retail markups of 50% to 100%). Generally,
outlets that received training and job aids performed better than those receiving one or
none of these intervention components
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: A random list of all eligible sublo-
cations was formulated per district in Microsoft
Excel. The first intervention sublocation was se-
lected from the top of the list. In order to reduce
the potential for contamination a “buffer zone”
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Kangwana 2013 (Continued)
was created where all sublocations located within
two sublocation boundaries of the selected sublo-
cation were removed from the list. The list was
reshuffled randomly and the first sublocation on
the new list allocated to the control arm
Allocation concealment (selection bias) Low risk Comment: The same procedure as for random
sequence generation (described above) was used;
intervention allocation could not have been seen
in advance
Baseline outcome measurements Low risk Comment:No important differences across study
groups on pre-specified subsidy outcome mea-
sures
Baseline characteristics Low risk Quote: “To control for potential confounders the
covariates consideredwere outlet type (specialized
drug store or general store), distance of shop to
nearest road, whether any staff had clinically re-
lated training, and district. All covariates signifi-
cant at a p-value of <0.2 were retained in the re-
gression model.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Blinding was not possible for shop-
keepers due to the public information campaign
around the subsidied drugs in the intervention
arm. Lack of blinding was, however, unlikely to
influence results as the outcomes assessed were
objective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Blinding was not possible for data col-
lectors due to the public information campaign
around the subsidised drugs in the intervention
arm. Lack of blinding was, however, unlikely to
influence results as outcomes assessed were objec-
tive
Contamination Low risk Quote: “It is also possible that there was some
contamination of the control arm outlets, which
could have heard some of the communication ac-
tivities. However, results indicated that such ex-
posure was low, with only 1% of control arm re-
spondents saying that they had attended the Tiba-
mal training, 14% having heard of Tibamal, and
no outlets stocking Tibamal.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In both the provider and mystery-shop-
per surveys, at baseline and also at follow-up, less
than 10% of outlets were not interviewed either
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Kangwana 2013 (Continued)
because the respondent refused to be interviewed
or the outlet was closed during visits.”
Selective reporting (reporting bias) Low risk Comment: Data on pre-specified outcomes were
reported
Recruitment bias Low risk Quote: “A random list of all eligible sublocations
was formulated per district in Microsoft Excel.
The first intervention sublocation was selected
from the top of the list...The list was reshuffled
randomly and the first sublocation on the new list
allocated to the control arm.”
Loss of clusters Low risk Quote: “We completed interviews in 2,319
homesteads at baseline (3,288households), and2,
204 homesteads at follow-up (3,182 households)
.All randomised clusters included in the analysis.
”
Incorrect analysis Low risk Quote: “A separate analysis allowing for clustering
within homesteads was also conducted.”
Comparability with individually ran-
domised trials
Low risk Comment: Included clusters comparable
Cohen 2015
Methods Cluster-randomised controlled trial
Participants Country: Kenya
Setting (coverage): Three rural districts (Busia, Mumias and Samia in Western Kenya)
Outlets: Retail outlets (drug shops)
Age group: All age groups
Interventions Households were randomly assigned to one of three groups:
(1) “No subsidy” group (“received vouchers to purchase unsubsidized ACTs at themarket
price of KSh (Kenyan shillings) 500 (just under $6.25). This treatment arm was meant
to capture the no-subsidy status quo that prevailed in Kenya prior to the AMFm pilot,
in which over-the-counter ACTs were expensive and RDTs were not available in drug
shops.”)
(2) ACT subsidy only group
(3) ’ACT plus RDT’ subsidy group (received vouchers for both subsidised ACTs and
RDTs)
The ACT used in the study was Coartem (AL).
Supportive interventions: None.
Outcomes Outcomes of interest to current review:
ACT accessibility (“the share of illness episodes treated with ACTs”);
ACT targeting (“the share of ACT-takers who are malaria positive”)
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Notes “Within the two ACT subsidy groups (’ACT subsidy only’ and ’ACT+RDT subsidy’)
, households were randomly assigned to an ACT subsidy level of 92, 88 or 80 percent
(corresponding to $0.50, $0.75 and $1.25 for an adult dose, respectively). The 92 percent
subsidy level corresponds to the Kenyan government’s target retail price of KSh 40 under
the AMFm.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization of households was
done using a computerized random number as-
signment algorithm and was stratified by drug
shop, by the household’s distance to the drug shop
(in quartiles) and by the presence of children in
the household.”
Allocation concealment (selection bias) Low risk Comment: The same procedure as for random
sequence generation (described above) was used;
selection bias due to foreknowledge of treatment
allocation is considered unlikely
Baseline outcome measurements Low risk Quote: “There are no significant differences
across treatment groups, other than for the num-
ber of acres owned and the age distribution in the
household. In particular, our control group has
slightly older household heads, with, as a conse-
quence, a significantly higher fraction of adults.
Since age is highly correlated with malaria posi-
tivity, a lack of balance across treatment groups
in the age composition of households could con-
found estimates of treatment assignment on up-
take and targeting, even though the magnitude
of the age differences is not large. Therefore, un-
less otherwise noted, we control for the age of the
household head in all of our results. ”
Baseline characteristics Low risk Quote: “There are no significant differences
across treatment groups, other than for the num-
ber of acres owned and the age distribution in the
household. In particular, our control group has
slightly older household heads, with, as a conse-
quence, a significantly higher fraction of adults.
Since age is highly correlated with malaria posi-
tivity, a lack of balance across treatment groups
in the age composition of households could con-
found estimates of treatment assignment on up-
take and targeting, even though the magnitude
of the age differences is not large. Therefore, un-
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Cohen 2015 (Continued)
less otherwise noted, we control for the age of the
household head in all of our results.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Lack of blinding considered unlikely
to impact on outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Lack of blinding considered unlikely
to impact on outcomes
Contamination Low risk Comment: Households were provided with
vouchers for subsidised and non-subsidised
ACTs; cross-group contamination is considered
unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Only five percent of households surveyed
at baseline were not reached at endline, and attri-
tion was balanced across treatment arms.”
Selective reporting (reporting bias) Low risk Comment: Data on pre-specified outcomes were
reported.
Recruitment bias Low risk Quote: “We selected four drug shops, in four rural
market centers and sampled all households in the
catchment area (within a 4km radius) of each of
these shops.”
“The randomization of households was done us-
ing a computerized random number assignment
algorithm and was stratified by drug shop, by the
household’s distance to the drug shop (in quar-
tiles) and by the presence of children in the house-
hold.”
Loss of clusters Low risk Quote: “Only five percent of households surveyed
at baseline were not reached at endline, and attri-
tion was balanced across treatment arms.”
Incorrect analysis Low risk Comment: Multivariable regression analysis al-
lowing for clustering used (e.g. “If more than one
household member got sick simultaneously, we
include all concurrent first episodes, and therefore
cluster the standard errors in all illness episode re-
gressions at the household level.”
Comparability with individually ran-
domised trials
Low risk Comment: Included clusters comparable
ACT = artemisinin-based combination therapy
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AL = artemether-lumefantrine
AQ = amodiaquine
RDT = rapid diagnostic test
SP = sulphadoxine-pyrimethamine
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Laxminarayan 2006 Not an RCT, NRCT, CBA or ITS: mathematical modelling study comparing impact of introduction of ACT
subsidy with scenarios in which artemisinin monotherapy and partner drug monotherapy are used in a small
proportion of patients in the absence of ACTs
MENTOR 2010 Not an RCT, NRCT, CBA or ITS: uncontrolled pilot of ACT implementation in two municipalities
Alba 2010 Not an RCT, NRCT, CBA or ITS: annual census of drug shops, retail audits of public, mission and private
outlets complemented with demographic surveillance system data
Cohen 2010 Not an RCT, NRCT, CBA or ITS: pre/post survey examining equity and spatial distribution of outcomes in
the delivery of subsidised private sector ACTs
Yeung 2011 Not anRCT,NRCT,CBAor ITS: documentation of programmatic experience of implementationof subsidised
ACT in the private sector
Smith 2011 Not an RCT, NRCT, CBA or ITS: census of public and private facilities, chemists, pharmacies, other malaria
medicine retailers
Rutta 2011 Not an RCT, NRCT, CBA or ITS: pre/post program evaluation (approximately one year after the introduction
of subsidised AL in accredited drug dispensing outlet)
Tougher 2012 Not an RCT, NRCT, CBA or ITS: before-and-after design with no comparator sites
Yadav 2012 Not an RCT, NRCT, CBA or ITS: periodic retail audits of accredited drug dispensing outlets to examine
availability and price of subsidised ACT during the first year of the AMFm
Yamey 2012 Not an RCT, NRCT, CBA or ITS: ’mixed-methods’ design, triangulating data from a literature review with
information from interviews with experts
Davis 2013 Not an RCT, NRCT, CBA or ITS: interview study of ACT availability and use in the private sector of five
AMFm phase 1 countries
O Meara 2013 Not an RCT, NRCT, CBA or ITS: study examines factors associated with retailers’ likelihood of stocking
subsidised AL and the association between price and sales for AL, quinine and sulphadoxine-pyrimethamine
Kedenge 2013 Not an RCT, NRCT, CBA or ITS: qualitative study (focus group discussions) to understand the impact of
subsidising ACTs in the retail sector
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Malm 2013 Not an RCT, NRCT, CBA or ITS: document review of policies, guidelines, reports, meeting minutes, and
Internet search of literature on implementation of AMFm
Fink 2013 Not an RCT, NRCT, CBA or ITS: periodic household and retail outlet surveys
Tougher 2014 Not an RCT, NRCT, CBA or ITS: before-and-after design with no comparator sites
ACT = artemisinin-based combination therapy
AL = artemether-lumefantrine
AMFm = Affordable Medicines Facility-malaria
CBA = controlled before-after
ITS = interrupted time series
NRCT = non-randomised controlled trial
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Guidelines for success benchmarks at 1 and 2 years after effective start date of the AMFm Phase 1 at the country level
Outcome Year 1 Year 2
Availability
(The proportion of all facilities, private and
public (including informal outlets), stock-
ing QAACTs, among outlets with any anti-
malarials in stock at the time of the survey)
Increase of 20 percentage points from
baseline
Increase of 40 percentage points from
baseline
Market share
(Total volume of QAACTs sold or dis-
tributed as a proportion of the total volume
of all antimalarials sold or distributed in the
last 7 days via outlets that will be included
in the Independent Evaluation’s outlet sur-
veys)
Increase in ACT market share of 10 to 15
percentage points from baseline and
Decrease in market share of AMT from
baseline
Increase in ACT market share of 15 to 20
percentage points from baseline and
Decrease in market share of AMT from
baseline
Usea
(Proportion of children under age 5 with
fever who received a QAACT on the day
that the fever started or on the following
day)
Increase of 5 to 10 percentage points
from baseline
Increase of 10 to 15 percentage points
from baseline
Price
(Adult equivalent treatment dose)
QAACT price < 300% of the price of the
dominant non-QAACT (inmost countries
this is CQ or SP)b and
Price of AMFm co-paid QAACT < price of
AMT (this is useful but not sufficient to
determine success)
QAACT price < 150% of the price of the
dominant non-QAACT (inmost countries
this is CQ or SP) and
Price of AMFm co-paid QAACT < price
of AMT (this is useful but not sufficient to
determine success)
ACT = artemisinin-based combination therapy; AMT = artemisinin monotherapy
AMFm = Affordable Medicines Facility-malaria
CQ = chloroquine
QAACT = quality-assured artemisinin-based combination therapies
SP = sulphadoxine-pyrimethamine
aThe denominator for ACT use is ’fever episodes in children under age 5’ (not ’parasitologically confirmed malaria cases’). The
Independent Evaluation relies on national surveys (e.g. demographic and health surveys, multiple indicator cluster surveys, malaria
indicator surveys and ACTwatch surveys), which use the denominator ’fever episodes in children under age 5’ due to a lack of proper
malaria diagnosis in many countries
bPrice change was the indicator with the weakest empirical basis for setting a 1-year expectation
Source: Yamey 2012
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Table 2. Characteristics of included studies
Study
Design
Country
Age group
Interven-
tiona
Co-inter-
vention
Outlet Coverage Data collec-
tion
Price
subsidy
Duration
Cohen 2015
Cluster-
RCT
Kenya
All age
groups
Subsidised
AL
None Drug shops 3 rural dis-
tricts
Household
surveys
80% to 92% 4 months
Kangwana
2011
Cluster-
RCT
Kenya
Children
under age 5
Subsidised
AL
Training of
retail outlet
staff
Job aids
Commu-
nity aware-
ness activi-
ties
Spe-
cialised and
general drug
storesb
3 rural dis-
tricts
(9 interven-
tion
and 9 con-
trol subloca-
tions)
Household
surveys
95% 1 year
Kangwana
2013
Cluster-
RCT
Kenya
Children
under age 5
Subsidised
AL
Training of
retail outlet
staff
Job aids
Commu-
nity aware-
ness activi-
ties
Spe-
cialised and
general drug
storesb
3 rural dis-
tricts
(9 interven-
tion
and 9 con-
trol subloca-
tions)
Provider
surveys
Mys-
tery shopper
surveys
95% 1 year
Sabot 2009
Non-
randomised
cluster trial
Tanzania
All age
groups
Subsidised
AL
Behaviour
change com-
mu-
nication (lo-
cal radio ad-
vertise-
ments, wall
paintings,
themed cul-
tural shows)
Small drug
shops (duka
la dawa
baridi)
3 rural dis-
tricts
(2 interven-
tion and 1
control)
Outlet exit
interviews
Mystery
shoppers
Outlet
audits
Public facil-
ity audits
90% 1 year
Talisuna
2012c
Non-
randomised
cluster trial
Uganda
All age
groups
Subsidised
AL
Training
of drug shop
attendants
Branding
(‘ACTwith a
leaf ’)
Communi-
cation activ-
ities
Drug shops
Private clin-
ics
Pharmacies
5 districts
(4 interven-
tion and 1
control)
Outlet exit
interviews
Outlet
audits
95% 20 months
ACT = artemisinin-based combination therapy
AL = artemether-lumefantrine
NGO = non-governmental organisation
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RCT = randomised controlled trial
aAll studies: no ACT subsidy interventions were implemented in the control sites; malaria diagnosis was predominantly presumptive
based on the presence of fever; exemption was granted for ACTs to be provided over the counter in the intervention sites; AL was
repackaged in weight specific packs and marked with recommended retail prices to inform consumers the maximum amount they
should pay
bSpecialised drug stores (registered or unregistered pharmacies) and general stores (which sold medicines alongside general household
goods)
cThere was better availability of ACT in the public sector in the control district because of improvements in the procurement and
distribution system, and supply by one NGO
Table 3. Percentage of children with fever who received ACT on the same day or following day of fever onset
Study Design Age group Control Intervention Absolute dif-
ference (95%
CI)
Relative effect
(95% CI)
Baseline Follow-up Baseline Follow-up
Kangwana
2011
Cluster-
RCT
Children
under age 5
5.3% 19.9% 4.7% 44.9% 25.0%(14.1%
to 35.9%)a
NR
Talisuna
2012
Non-
randomised
cluster trial
Children
under age 5
NR 2% NR 18% 16.0%b OR 10.0 (4.96
to 18.86)c
ACT = artemisinin-based combination therapy
CI = confidence interval
NR = not reported
OR = odds ratio
RCT = randomised controlled trial
aThere was no correlation between socio-economic status and use of AL (p=0.875) or Tibamal, subsidised AL (p=0.745)
bEstimated assuming similar baseline values in control and intervention groups
cAll age groups: patients in the intervention districts had a six-fold increase in ACT use relative to the control district (95% CI 4.22
to 8.44). Use of ACT was higher in the highest socio-economic status stratum compared to the lowest stratum (OR 2.4, 95% CI 1.72
to 3.35, p<0.001); estimated from available data
Table 4. National ACT subsidy programmesa
Country Lead organi-
sation
Launch year Age group Outlets Coverage Outcome:
ACT
availability
Outcome:
ACT price
Cambodia PSI 2002 All age groups Pharmacies
Drug shops
17 of
20 malaria-en-
demic
provinces
At 1 year: very
low in private
facilities (22%
stocked adult
ACTs, 6%
stocked child
ACTs)
At
1 year: mean
consumer
price for adult
ACTs (US$ 1.
07) 70%
higher than
RRP (US$ 0.
63)
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Table 4. National ACT subsidy programmesa (Continued)
Cameroon Government 2007 All age groups Public and pri-
vate health fa-
cilities
National At 1 year: low
availability of
subsidised
ACTs at public
and private fa-
cilities,
monotherapies
widely
available
At 1 year: ad-
her-
ence to RRP
strong in only
one province
(YaoundéCen-
tre)
DRC PSI 2006 Children < age
5
Pharmacies Limited to
some districts
At
2 years: ACTs
available in 20.
2% (public fa-
cilities), 25.8%
(part 1 phar-
macies), 20%
(drug shops)
, 8.6% (other
private outlets)
; 66.4% of fa-
cilities stocked
non-ACTs,
47.8% stocked
AMT
At 2 years: me-
dian price of
ACTs: US$ 2.
75
(public health
facilities), US$
2.29-4.58 (pri-
vate facilities),
US$ 3.89 (all
facilities selling
ACTs)
; ACT price
60% higher
than price of
the most com-
mon
antimalarial in
outlets selling
ACTs
Madagascar PSI 2003 Children < age
5
Pharmacies
Private
providers
Community
agents
National At 5 years: 85.
6% (public fa-
cilities), 47.5%
(part 1 phar-
macies), 20%
(drug shops),
0.1-
16.5% (other
private outlets)
; 34.4% of fa-
cilities stocked
non-ACT,
0.5% stocked
AMT
At 5 years: me-
dian price of
ACTs in fa-
cilities selling
ACTs was US$
4.
04 (ACTs free
in public facili-
ties); ACTs 11.
3 times more
expensive than
the most com-
mon
antimalarial in
outlets selling
ACTs
Rwanda PSI 2007 Children < age
5
Pharmacies National At 18 months:
high
Data unavail-
able
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Table 4. National ACT subsidy programmesa (Continued)
ACT availabil-
ity in private
pharma-
cies (80-90%
stocked child
ACTs
compared with
10% at base-
line)
; monothera-
pies effectively
banned
Senegal Government 2006 All age groups Pharmacies National At 1 year: pro-
portion of all
facilities (pub-
lic and private)
stocking ACTs
was 44.8%
(adult dose),
58.2% (child),
46.3% (infant)
; monothera-
pies widely
available
At 1 year:
strong adher-
ence to RRP
in private out-
lets (observed
mean retail
price = US$ 1.
34;RRP=US$
1.31)
ACTs = artemisinin-based combination therapies
AMFm = Affordable Medicines Facility-malaria
AMT = artemisinin monotherapy
PSI = Population Services International
RRP = recommended retail price
aThese programmes were rolled out before the 2010-11 AMFm pilot. Two countries - Cambodia and Madagascar - have also been
included in the AMFm pilot phase and the results from the pilot are due to be reported in 2012
Source: Yamey 2012
Table 5. Percentage of retail outlets stocking ACTs
Study Design Age group Control Intervention Difference (95% CI)
Baseline Follow-up Baseline Follow-up
Kangwana
2011
Cluster-RCT Children un-
der age 5
0.5% 5.5% 2.4% 37.6% 31.9% (26.3% to 37.5%)
Kangwana
2013
Cluster-RCT Children un-
der age 5
0.5% 5.2% 1.5% 36.8% 31.7% (22.0% to 41.3%)
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Table 5. Percentage of retail outlets stocking ACTs (Continued)
Sabot 2009 Non-ran-
domised clus-
ter trial
All age groups 1.0% 0% 0% 72.2% 72.2% (65.0% to 79.3%)
a
ACT = artemisinin-based combination therapy
CI = confidence interval
RCT = randomised controlled trial
aDrug shops in population centres were more likely to stock ACTs than those in more remote areas (P < 0.001)
Table 6. Change in ACT price to patients
Study Design Age group Outcome def-
inition
Group Baseline costs
a
Follow up
costa
Data collec-
tion method
Kangwana
2011
Cluster-RCT Under age 5 Median
cost per ACT
course
Control
Intervention
US$ 1.08
(US$ 0.18)
US$ 0.9 (US$
0.15)
US$ 0.84
(US$ 0.14)
US$ 0.24
(US$ 0.04)
US$ 0.84 per
ACT course
(IQR not es-
timable)b,c
Kangwana
2013
Cluster-RCT Under age 5 Cost per ACT
course (2
doses)
Control
Intervention
NR
2 doses each
US$ 2.46 and
US$ 2.22
NR
US$ 0.25
Not estimable
Sabot 2009 Non-ran-
domised clus-
ter trial
Under age 5d Mean price for
ACT
Mean price for
SP
Mean price for
AQ
Intervention NR US$ 0.19
US$ 0.51
US$ 0.86
Not estimable
Talisuna 2012 Non-ran-
domised clus-
ter trial
Under age 5 ’Retail price
for ACT’
Control
Intervention
NR “Maximum
recommended
retail price was
within 10% of
the recom-
mended ACT
price)”e
Not estimable
ACT = artemisinin-based combination therapy
AQ = amodiaquine
IQR = interquartile range
NR = not reported
RCT = randomised controlled trial
SP = sulphadoxine-pyrimethamine
aACT treatment course: six tablets (for children aged 3-35 months) and 12 tablets (for children aged 36-59 months) - cost estimates
based on ACT course for children aged 3-35 months
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bDifference between baseline cost per ACT course (control group: US$ 1.08) and follow-up cost per ACT course (intervention group:
US$ 0.24)
cAt follow-up, 95.3% of caregivers in the intervention arm who bought subsidised AL said they purchased it at the recommended retail
price of US$ 0.25. Of the eight not paying this price, three paid less than US$ 0.25 and five paid between US$ 0.31 and US$ 1.23
dAll age groups: the mean price for ACTs (US$ 0.58) did not differ from the price of SP (US$ 0.67), but was higher than for AQ (US$
0.48, P < 0.001)
eThe recommended retail price for an adult course of treatment - US$ 0.47 - was not adhered to (the median price at the endline
survey was US$ 1.96)
Table 7. ACT purchases, sales or market share
Study Design Age group Outcome
definition
Control Intervention Difference
(95% CI)
Baseline Follow-up Baseline Follow-up
Kangwana
2011
Cluster-
RCT
Children <
age 5
Total vol-
ume of AL
dispensed at
general
stores
0% 0% 0% 63.0% 63%a
Total vol-
ume of AL
dispensed in
specialised
drug stores
1.0% 11.0% 0% 65.0% 55%a
Kangwana
2013
Cluster-
RCT
Children <
age 5
Total vol-
ume of AL
sold to mys-
tery
shoppers
0.5% 1.8% 0% 25.4% 23.6% (18.7%
to 28.6%)
Sabot 2009 Non-
randomised
cluster trial
Adults≥ age
16
Total
volume of
ACTs
purchased
0% 0% 1.0% 35.0% 35.3 % (29.8%
to 40.7%)b,c
Children <
age 5
Total
volume of
ACTs
purchased
0% 6.0% 0% 53.0% 8.9% (-0.5% to
18.2%)d
Talisuna
2012
Non-
randomised
cluster trial
All age
groups
Total
volume of
ACTs
purchased as
a proportion
of the total
volume of all
NR NR 43% 69% NR
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Table 7. ACT purchases, sales or market share (Continued)
anti-
malarials
purchased
via outlets
Total
volume of
ACTs
purchased
1.8% 5.6% 0.8% 26.2% 21.6%a,e
ACT = artemisinin-based combination therapy
AL = artemether-lumefantrine
AQ = amodiaquine
CI = confidence interval
NR = not reported
RCT = randomised controlled trial
SP = sulphadoxine-pyrimethamine
a95% CI not estimable from the reported data
bThere was no correlation between the socio-economic status of the consumer and the likelihood of buying ACTs
cPurchases of SP and AQ in the intervention districts declined from 68.0% to 51.0% and 26.0% to 11.0% respectively. Purchases of
SP in the control district increased from 62.0% to 83.0% while for AQ declined from 33% to 16.0%
dPurchases of SP in the intervention districts decreased from 7.0% to 4.0% and remained the same at 9.0% in the control district.
Purchases of AQ in the intervention districts declined from 91.0% to 36.0%, and from 91.0% to 36.0% in the control district
eThe market shares for chloroquine and quinine were 5% and 24% respectively at the end of the pilot; Children less than five years
had subsidised ACTs purchased for them more often than those aged above 5 years
Table 8. Use of older antimalarials
Study Design Age group Outcome
definition
Control Intervention Difference
(95% CI)
Rel-
ative effect
(95% CI)Baseline Follow-up Baseline Follow-up
Kangwana
2011
Cluster-
RCT
Children <
age 5
Use of an-
timalarial
monother-
apya
29.8% 22.8% 39.0% 12.4% -10.4% (-
3.9% to -
16.9%)
NR
Talisuna
2012
Non-ran-
domised
cluster trial
All age
groups
Use of qui-
nine
NR 44% NR 37% NR OR 0.
76 (0.53 to
1.08)
CI = confidence interval
NR = not reported
OR = odds ratio
RCT = randomised controlled trial
aamodiaquine, suphadoxine-pyrimethamine and quinine
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A P P E N D I C E S
Appendix 1. EPOC review study designs
Suggested terms Definition Exclusions
Randomised controlled trial (RCT) OR,
preferably, randomised trial
An experimental study in which people are
allocated to different interventions using
methods that are random
Studies with only one intervention or
control site
We recommend only including cluster ran-
domised trials, non-randomised cluster tri-
als, and CBA studies with at least two in-
tervention sites and two control sites
In studies with only one intervention or
control site the intervention (or compari-
son) is completely confoundedby study site
making it difficult to attribute any observed
differences to the intervention rather than
to other site-specific variables
Non-randomised controlled trial (NRCT)
OR, preferably, non-randomised trial
An experimental study in which people are
allocated to different interventions using
methods that are not random
Controlled before-after (CBA) study A study in which observations are made
before and after the implementation of an
intervention, both in a group that receives
the intervention and in a control group that
does not
Interrupted-time-series (ITS) study A study that uses observations at multiple
time points before and after an intervention
(the ‘interruption’). The design attempts to
detect whether the intervention has had an
effect significantly greater than any under-
lying trend over time
Studies that do not have a clearly defined
point in time when the intervention oc-
curred and at least three data points be-
fore and three after the intervention
Repeated measures study (RMS) An ITS study where measurements are
made in the same individuals at each time
point
Appendix 2. Search strategies
CENTRAL, Cochrane Library
#1 MeSHdescriptor: [Artemisinins] this term only andwith qual-
ifier(s): [Economics - EC, Supply & distribution - SD]
16
#2 MeSH descriptor: [Sesquiterpenes] this term only and with
qualifier(s): [Economics - EC, Supply & distribution - SD]
5
#3 #1 or #2 18
#4 MeSH descriptor: [Artemisinins] this term only 657
#5 MeSH descriptor: [Sesquiterpenes] this term only 412
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(Continued)
#6 (artemisinin or artemisinins or artemisinine or artemisinines or
artemisin or artemisins or artemisine or artemisines or arteann-
uin or “ching hao su” or chinghaosu or ginghaosu or qinghaosu
or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene
or artemether or artemetero or artemetherum or artenam or
arthemether or paluther or “co artem” or “co artemether” or
coartem or coartemether or riamet):ti,ab,kw
1007
#7 #4 or #5 or #6 1007
#8 MeSH descriptor: [Cost Sharing] this term only 25
#9 MeSH descriptor: [Cost Allocation] this term only 16
#10 MeSH descriptor: [Drug Costs] this term only 1689
#11 MeSHdescriptor: [Economics, Pharmaceutical] this term only 236
#12 MeSH descriptor: [Commerce] this term only 112
#13 MeSH descriptor: [Financial Management] this term only 14
#14 MeSH descriptor: [Budgets] this term only 65
#15 MeSH descriptor: [Rate Setting and Review] this term only 0
#16 MeSH descriptor: [Marketing of Health Services] this term
only
43
#17 MeSH descriptor: [Social Marketing] this term only 137
#18 MeSH descriptor: [Financial Support] this term only 20
#19 MeSH descriptor: [Financing, Government] this term only 56
#20 MeSH descriptor: [Financing, Organized] this term only 22
#21 MeSH descriptor: [Fees and Charges] this term only 66
#22 MeSH descriptor: [Fees, Pharmaceutical] this term only 25
#23 (subsidy or subsidies or subsidis* or subsidiz*):ti,ab,kw 143
#24 (financing or funding):ti,ab,kw 2733
#25 (co next pay* or copay*):ti,ab,kw 87
47Subsidising artemisinin-based combination therapy in the private retail sector (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
#26 (pocket near/3 pay*):ti,ab,kw 13
#27 (voucher or vouchers):ti,ab,kw 272
#28 (financial or monetary) near/3 (support or assistance or help
or aid or backing):ti,ab,kw
153
#29 (reduce* or lower* or limit* or share or shared or sharing or cut
or cutting) near/3 (cost or costs or price or prices or payment*
or spending or expenditure):ti,ab,kw
3383
#30 (drug or drugs or medicine* or medicament* or pharmaceu-
tic*) near/3 (econom* or cost or costs or fee or fees or budget*
or affordable or marketing):ti,ab,kw
5562
#31 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or
#25 or #26 or #27 or #28 or #29 or #30)
11904
#32 MeSH descriptor: [Private Sector] this term only 41
#33 MeSH descriptor: [Public-Private Sector Partnerships] this
term only
8
#34 privat*:ti,ab,kw 2215
#35 retail*:ti,ab,kw 118
#36 (#32 or #33 or #34 or #35) 2324
#37 (#31 or #36) 14025
#38 (#3 or (#7 and #37)) in Trials 41
MEDLINE, OvidSP
# Searches Results
1 Artemisinins/ec, sd [Economics, Supply & Distribution] 178
2 Sesquiterpenes/ec, sd [Economics, Supply & Distribution] 42
3 or/1-2 187
4 Artemisinins/ 4435
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(Continued)
5 Sesquiterpenes/ 11844
6 (artemisinin or artemisinins or artemisinine or artemisinines or
artemisin or artemisins or artemisine or artemisines or artean-
nuin or ching hao su or chinghaosu or ginghaosu or qinghaosu
or quinghaosu or quinhaosu or sesquiterpenes or sesquiter-
pene or artemether or artemetero or artemetherum or artenam
or arthemether or paluther or co artem or co artemether or
coartem or coartemether or riamet).ti,ab
9803
7 or/4-6 17929
8 “Cost Sharing”/ 2004
9 “Cost Allocation”/ 1945
10 Drug Costs/ 12407
11 Economics, Pharmaceutical/ 2550
12 Commerce/ 18154
13 Financial Management/ 15422
14 Budgets/ 9877
15 “Rate Setting and Review”/ 2474
16 Marketing of Health Services/ 14065
17 Social Marketing/ 2076
18 Financial Support/ 3039
19 Financing, Government/ 18745
20 Financing, Organized/ 5804
21 “Fees and Charges”/ 8196
22 Fees, Pharmaceutical/ 1141
23 (subsidy or subsidies or subsidis* or subsidiz*).ti,ab. 4892
24 (financing or funding).ti,ab. 39957
25 (co pay* or copay*).ti,ab. 1557
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(Continued)
26 (pocket adj3 pay*).ti,ab. 571
27 voucher?.ti,ab. 1052
28 ((financial or monetary) adj3 (support or assistance or help or
aid or backing)).ti,ab
4544
29 ((reduce* or lower* or limit* or share or shared or sharing or
cut or cutting) adj3 (cost? or price? or payment? or spending
or expenditure)).ti,ab
38933
30 ((drug or drugs or medicine? or medicament? or pharmaceu-
tic*) adj3 (econom* or cost or costs or fee or fees or budget? or
affordable or marketing)).ti,ab
11651
31 or/8-30 190651
32 Private Sector/ 7513
33 Public-Private Sector Partnerships/ 1171
34 privat*.ti,ab. 63212
35 retail*.ti,ab. 6482
36 or/32-35 73669
37 randomized controlled trial.pt. 384812
38 controlled clinical trial.pt. 88618
39 pragmatic clinical trial.pt. 109
40 multicenter study.pt. 179454
41 non-randomized controlled trials as topic/ 11
42 interrupted time series analysis/ 16
43 controlled before-after studies/ 25
44 (randomis* or randomiz* or randomly or random allocat*).ti,
ab
586424
45 groups.ab. 1414883
46 (trial or multicenter or multi center or multicentre or multi
centre).ti
156461
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(Continued)
47 (intervention* or controlled or control or compare or compared
or (before adj5 after) or (pre adj5 post) or pretest or pre test or
posttest or post test or quasiexperiment* or quasi experiment*
or evaluat* or effect or impact or time series or time point? or
repeated measur*).ti,ab
7687512
48 or/37-47 8282037
49 exp Animals/ 17689330
50 Humans/ 13699500
51 49 not (49 and 50) 3989830
52 review.pt. 1937353
53 meta analysis.pt. 53160
54 news.pt. 166715
55 comment.pt. 612267
56 editorial.pt. 369594
57 cochrane database of systematic reviews.jn. 10975
58 “comment on”.cm. 612267
59 (systematic review or literature review).ti. 57183
60 or/51-59 6788530
61 48 not 60 5826774
62 3 and 61 76
63 7 and (31 or 36) and 61 192
64 62 or 63 [Artemisinin AND subsidy or private ANDMethods] 216
Embase, OvidSP
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# Searches Results
1 artemisinin/ 4920
2 artemisinin derivative/ 2097
3 sesquiterpene/ 5893
4 sesquiterpene derivative/ 2636
5 artemether/ 2243
6 artemether plus benflumetol/ 1792
7 (artemisinin or artemisinins or artemisinine or artemisinines or
artemisin or artemisins or artemisine or artemisines or artean-
nuin or ching hao su or chinghaosu or ginghaosu or qinghaosu
or quinghaosu or quinhaosu or sesquiterpenes or sesquiter-
pene or artemether or artemetero or artemetherum or artenam
or arthemether or paluther or co artem or co artemether or
coartem or coartemether or riamet).ti,ab
13715
8 or/1-7 20543
9 (“Health Policy, Economics and management” or “36”).ec. 467908
10 drug cost/ 60104
11 commercial phenomena/ 27879
12 drug marketing/ 26589
13 social marketing/ 2703
14 financial management/ 102311
15 budget/ 20306
16 fee/ 14380
17 medical fee/ 11634
18 pharmacoeconomics/ 6029
19 (subsidy or subsidies or subsidis* or subsidiz*).ti,ab. 5621
20 (financing or funding).ti,ab. 47405
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(Continued)
21 (co pay* or copay*).ti,ab. 2279
22 (pocket adj3 pay*).ti,ab. 709
23 voucher?.ti,ab. 1226
24 ((financial or monetary) adj3 (support or assistance or help or
aid or backing)).ti,ab
5864
25 ((reduce* or lower* or limit* or share or shared or sharing or
cut or cutting) adj3 (cost? or price? or payment? or spending
or expenditure)).ti,ab
50681
26 ((drug or drugs or medicine? or medicament? or pharmaceu-
tic*) adj3 (econom* or cost or costs or fee or fees or budget? or
affordable or marketing)).ti,ab
18354
27 or/9-26 708923
28 public-private partnership/ 2922
29 privat*.ti,ab. 76514
30 retail*.ti,ab. 7520
31 or/28-30 85785
32 Randomized Controlled Trial/ 359286
33 Controlled Clinical Trial/ 390010
34 Quasi Experimental Study/ 2249
35 Pretest Posttest Control Group Design/ 220
36 Time Series Analysis/ 14920
37 Experimental Design/ 10689
38 Multicenter Study/ 114984
39 (randomis* or randomiz* or randomly or random allocat*).ti,
ab
761973
40 groups.ab. 1772331
41 (trial or multicentre or multicenter or multi centre or multi
center).ti
202335
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(Continued)
42 (intervention* or controlled or control or compare or compared
or (before adj5 after) or (pre adj5 post) or pretest or pre test or
posttest or post test or quasiexperiment* or quasi experiment*
or evaluat* or effect or impact or time series or time point? or
repeated measur*).ti,ab
9136496
43 or/32-42 9809305
44 (systematic review or literature review).ti. 67987
45 “cochrane database of systematic reviews”.jn. 3776
46 Nonhuman/ 4447094
47 or/44-46 4517005
48 43 not 47 7715761
49 8 and (27 or 31) and 48 551
50 limit 49 to embase 513
CINAHL, EbscoHost
Top of Form
# Query Results
S1 TX
(artemisinin or artemisinins or artemisinine or artemisinines or
artemisin or artemisins or artemisine or artemisines or arteann-
uin or “ching hao su” or chinghaosu or ginghaosu or qinghaosu
or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene
or artemether or artemetero or artemetherum or artenam or
arthemether or paluther or “co artem” or “co artemether” or
coartem or coartemether or riamet) Limiters - Exclude MED-
LINE records
51
Regional Indexes, Global Health Library, WHO
(artemisinin or artemisinins or artemisinine or artemisinines or artemisin or artemisins or artemisine or artemisines or arteannuin or
chinghaosu or ginghaosu or qinghaosu or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene or artemether or artemetero or
artemetherum or artenam or arthemether or paluther or coartem or coartemether or riamet) AND (subsidy or subsidies or subsidis* or
subsidiz* or commerce or finance* or funding or affordable or marketing or privat* or retail*)
LILACS, Global Health Library, WHO
(artemisinin or artemisinins or artemisinine or artemisinines or artemisin or artemisins or artemisine or artemisines or arteannuin or
chinghaosu or ginghaosu or qinghaosu or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene or artemether or artemetero or
artemetherum or artenam or arthemether or paluther or coartem or coartemether or riamet)
Science Citation Index and Social Sciences Citation Index (ISI Web of Science)
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Topic search
(artemisinin or artemisinins or artemisinine or artemisinines or artemisin or artemisins or artemisine or artemisines or arteannuin or
“ching hao su” or chinghaosu or ginghaosu or qinghaosu or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene or artemether
or artemetero or artemetherum or artenam or arthemether or paluther or “co artem” or “co artemether” or coartem or coartemether or
riamet) (Topic)
AND
(subsidy or subsidies or subsidise or subsidised or subsidize or subsidized or subsidising or subsidizing or financing or funding) (Topic)
AND
(randomised or randomized or randomly or “random allocation” or trial or intervention or interventions or controlled or “control
group” or “before and after” or “pre and post” or pretest or “pre test” or posttest or “post test” or quasiexperiment or quasiexperimental
or “quasi experiment” or “quasi experimental” or evaluate or effect or impact or “time series” or “time point” or “time points” or
“repeated measure” or “repeated measures” or “repeated measurement” or “repeated measurements”) (Topic)
Science Citation Index and Social Sciences Citation Index (ISI Web of Science)
Citation search for all 4 included studies
Kangwana 2011
Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, Fegan GW, Todd JE, Brooker S, Snow RW, Goodman
CA. The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster
randomized controlled trial. PLoS Med 2011;8(5):e1000437.
Kangwana 2013
Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, Fegan GW, Todd JE, Snow RW, Goodman CA. The
effect of an anti-malarial subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a
cluster-randomized, controlled trial. Malar J 2013;12(81).
Sabot 2009
Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, Odhiambo M, Ward L, Goodman C. Piloting the global subsidy:
the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One
2009;4(9):e6857.
Talisuna 2012
Talisuna AO, Daumerie PG, Balyeku A, Egan T, Piot B, Coghlan R, Lugand M, Bwire G, Rwakimari JB, Ndyomugyenyi R, Kato
F, Byangire M, Kagwa P, Sebisubi F, Nahamya D, Bonabana A, Mpanga-Mukasa S, Buyungo P, Lukwago J, Batte A, Nakanwagi G,
Tibenderana J, Nayer K, Reddy K, Dokwal N, Rugumambaju S, Kidde S, Banerji J, Jagoe G. Closing the access barrier for effective
anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Malar J 2012;11:
356.
EconLit, ProQuest
ALL(artemisinin or artemisinins or artemisinine or artemisinines or artemisin or artemisins or artemisine or artemisines or arteannuin or
“ching hao su” or chinghaosu or ginghaosu or qinghaosu or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene or artemether
or artemetero or artemetherum or artenam or arthemether or paluther or “co artem” or “co artemether” or coartem or coartemether or
riamet)
Global Health, OvidSP
# Searches Results
1 (artemisinin or artemisinins or artemisinine or artemisinines or
artemisin or artemisins or artemisine or artemisines or artean-
nuin or ching hao su or chinghaosu or ginghaosu or qinghaosu
or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene
or artemether or artemetero or artemetherum or artenam or
arthemether or paluther or co artemor co artemether or coartem
or coartemether or riamet).mp
8409
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2 (subsidy or subsidies or subsidise or subsidised or subsidize or
subsidized or subsidising or subsidizing or commerce or financ-
ing or funding or affordable or marketing or private or retail or
retailer or retailers).mp
43253
3 (randomised or randomized or randomly or random allocation
or trial or intervention or interventions or controlled or control
group or (before adj5 after) or (pre adj5 post) or pretest or pre
test or posttest or post test or quasiexperiment or quasiexperi-
mental or quasi experiment or quasi experimental or evaluate
or effect or impact or time series or time point or time points
or repeated measure or repeated measures or repeated measure-
ment or repeated measurements).mp
737158
4 1 and 2 and 3 114
Health Management, ProQuest
ALL (artemisinin or artemisinins or artemisinine or artemisinines or artemisin or artemisins or artemisine or artemisines or arteannuin
or “ching hao su” or chinghaosu or ginghaosu or qinghaosu or quinghaosu or quinhaosu or sesquiterpenes or sesquiterpene or artemether
or artemetero or artemetherum or artenam or arthemether or paluther or “co artem” or “co artemether” or coartem or coartemether
or riamet) and ALL (subsidy or subsidies or subsidis* or subsidiz* or commerce or financing or funding or affordable or marketing or
private or retail or retailer or retailers) and ALL (randomised or randomized or randomly or “random allocation” or trial or intervention
or interventions or controlled or “control group” or “before and after” or “pre and post” or pretest or “pre test” or posttest or “post test”
or quasiexperiment or quasiexperimental or “quasi experiment” or “quasi experimental” or evaluate or effect or impact or “time series”
or “time point” or “time points” or “repeatedmeasure” or “repeated measures” or “repeatedmeasurement” or “repeated measurements”)
The Grey Literature Report from The New York Academy of Medicine Library
Combination of “artemisinin-based combination therapies, artemether, coartem, private sector, retail sector, retailers, drug shops,
pharmacies, public-private sector partnerships, Affordable Medicines Facility - malaria, AMFm, subsidies, co-payment, financing,
vouchers.”
International Clinical Trials Registry Platform (ICTRP), WHO
Combination of “artemisinin-based combination therapies, artemether, coartem, private sector, retail sector, retailers, drug shops,
pharmacies, public-private sector partnerships, Affordable Medicines Facility - malaria, AMFm, subsidies, co-payment, financing,
vouchers.”
ClinicalTrials.gov, NIH
Combination of “artemisinin-based combination therapies, artemether, coartem, private sector, retail sector, retailers, drug shops,
pharmacies, public-private sector partnerships, Affordable Medicines Facility - malaria, AMFm, subsidies, co-payment, financing,
vouchers.”
Appendix 3. GRADE evidence profile: ACT subsidies combined with supportive interventions
versus no subsidies
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Effects of retail sector ACT subsidy programmes on ACT use, availability, price and market share
Population: Patients seeking treatment for suspected uncomplicated malaria
Settings: East Africa (Kenya, Uganda, Tanzania)
Intervention: Retail sector ACT price subsidies plus supportive interventions (retail outlet provider training, community awareness
and mass media campaigns)
Comparison: Standard practice (no subsidies)
Quality assessment Effect
GRADE
quality
of the
evi-
dence
Impor-
tance
Num-
ber of
partici-
pants
(stud-
ies)
Design Risk of
bias
Incon-
sis-
tency
Indi-
rect-
ness
Impre-
cision
Other
consid-
era-
tions
With ACT sub-
sidy
No
ACT
subsidy
Abso-
lute dif-
ference
(95%
CI)
ACT use (percentage of children under 5 years of age receiving ACT on the same day or following day of fever onset)
2,662
(1
study)
Clus-
ter-
RCT
No seri-
ous risk
of bias
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
No seri-
ous im-
preci-
sion
None 30.
3% (19.
4% to
41.2%)
5.3% 25%
(14.1%
to 35.
9%)
⊕⊕⊕⊕
High
CRITI-
CAL
ACT availability (percentage of outlets stocking ACTs for children under 5 years of age)
1 study
re-
ported
in
2
articles
Clus-
ter-
RCT
No seri-
ous risk
of bias
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
No seri-
ous im-
preci-
sion
None 32.
4% (22.
5% to
41.8%)
<0.5% 31.
9% (26.
3% to
37.5%)
⊕⊕⊕⊕
High
CRITI-
CAL
ACT availability (percentage of outlets stocking at least one ACT for patients of any age)
1 study Non-
ran-
domised
cluster
trial
Serious
a
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
Serious
a
None 72.
7% (65.
5% to
79.8%
0.5% 72.
2% (65.
0% to
79.3%)
⊕ a
Very
low
CRITI-
CAL
ACT price (change in ACT price for children under 5 years of age) Median cost per ACT treatment course (6-12 tablets)
1 study Clus-
ter-
RCT
No seri-
ous risk
of bias
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
No seri-
ous im-
preci-
sion
None US$ 1.
08
US$ 0.24 US$ 0.
84
⊕⊕⊕⊕
High
CRITI-
CAL
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(Continued)
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased)
1 study
re-
ported
in
two ar-
ticles
Clus-
ter-
RCT
No seri-
ous risk
of bias
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
No seri-
ous im-
preci-
sion
None Range
25.
4% to
65.0%
Range 0% to 11.
0%
Range
23.6%
to 63.
0%
⊕⊕⊕⊕
High
CRITI-
CAL
Use of older antimalarials (amodiaquine, sulphadoxine-pyrimethamine) among children under five years of age
1 study Ran-
domised
trials
No seri-
ous risk
of bias
No seri-
ous in-
consis-
tency
No seri-
ous in-
direct-
ness
No seri-
ous im-
preci-
sion
None 24.
0% (17.
5% to
30.5%)
34.4% -10.
4% (-3.
9% to -
16.9%)
⊕⊕⊕⊕
High
CRITI-
CAL
Adverse effects (such as the number of people receiving ACTs who do not have malaria)
None of the three studies of ACT subsidies combined with supportive interventions assessed adverse effect outcomes
ACT = artemisinin-based combination therapy; RCT = randomised controlled trial
aDowngraded from low to very low due to high likelihood of selection bias (non-randomised design) and confounding by study site
(only one control site included; results likely to be influenced by site-specific factors)
Appendix 4. GRADE evidence profile: ACT vouchers versus no subsidies
Effects of ACT price vouchers on ACT accessibility and targeting
Population: Patients seeking treatment for suspected uncomplicated malaria
Settings: Three rural malaria endemic districts in Western Kenya
Intervention: ACT subsidy (ACT vouchers to households; 80 to 92% subsidy)
Comparison: No subsidy (households received vouchers to purchase unsubsidised ACTs at the pre-AMFm retail price)
Quality assessment Effect GRADE
quality
of the evi-
dence
Impor-
tance
Num-
ber of par-
ticipants
(studies)
Design Risk of
bias
Inconsis-
tency
Indirect-
ness
Impreci-
sion
Other
considera-
tions
ACT access (percentage of illness episodes treated with ACTs; all age groups; follow-up: 4 months)
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(Continued)
2,
789 house-
holds
(1 study)
Ran-
domised
trial
No serious
risk of bias
No serious
inconsis-
tency
No serious
indirect-
ness
No
serious im-
precision
None Com-
pared to an
access rate
of 19%
in the con-
trol group,
subsidies
of 80%
or more in-
creased the
like-
lihood that
a malaria-
like illness
is treated
with an
ACT by 16
to 23 per-
cent-
age points,
that is,
an 85% to
118% in-
crease
⊕⊕⊕⊕
High
IMPOR-
TANT
ACT targeting (percentage of ACT takers who are malaria positive; all age groups; follow-up: 4 months)
2,
789 house-
holds
(1 study)
Ran-
domised
trials
No serious
risk of bias
No serious
inconsis-
tency
No serious
indirect-
ness
No
serious im-
precision
None Sub-
sidies were
associ-
ated with a
high rate of
overtreat-
ment
of malaria
(only 56%
of patients
taking
ACTs from
the drug
shop tested
positive for
malaria
under the
92% sub-
sidy)
⊕⊕⊕⊕
High
IMPOR-
TANT
ACT = artemisinin-based combination therapy; AMFm = Affordable Medicines Facility-malaria
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Appendix 5. Planned methods not used in the review
Unit of analysis issues
Wewill assess whether appropriate analysis was conducted to adjust for clustering in estimating precision of effects in cluster randomised
trials and controlled before-after studies. Where clustering has not been accounted for, we will contact study authors, and if possible
work with them to re-analyse the results using standard approaches incorporating measures of intra-cluster correlation coefficients
(ICCs) (Higgins 2011). If re-analysis is not possible (e.g. due to lack of estimates of ICCs) we will report effect sizes without measures
of precision.
Assessment of heterogeneity
For a subset of studies where meta-analysis is considered appropriate (e.g. where study designs and interventions are sufficiently similar),
we will also explore heterogeneity using Chi2 tests (Cochran’s Q) and the I2 statistic following guidelines described in the Cochrane
Handbook for Systematic Reviews of Interventions. Where heterogeneity is detected, we will explore and report plausible explanations
for observed differences.
Data synthesis
We will consider combining results of subsets of studies using meta-analysis (random-effects method) where between-study differences
are considered unlikely to explain variability in treatment effects. We will present data used in the synthesis alongside observed results
using tables.
Where relevant, dichotomous data will be summarised using risk (or rate) ratios (with 95% confidence intervals (CIs)), while continuous
data will be summarised using mean differences (with 95% CIs). Where relevant data can be obtained, inappropriately analysed
interrupted-time-series’ will be re-analysed using time series regression to account for secular trends and potential autocorrelation (in
time) of data; the best fit pre-intervention and post-intervention line will be estimated using linear regression or autoregressive integrated
moving average techniques (Lagarde 2012; Ramsay 2003).
Subgroup analysis and investigation of heterogeneity
We anticipate the number of eligible studies will be small so we have therefore limited the subgroup analysis. We will explore consistency
of intervention effects in stratified analyses to examine whether the intervention indeed is pro-poor: participant socioeconomic status
(SES; low versus high SES quintiles; we will consider the poor as those in the lower three SES quintiles or those living on less
than $2 (purchasing power parity) per day (World Bank 2014). The following variables will be explored as possible explanations for
heterogeneity:
• Study designs
• Nature of supportive interventions (e.g. malaria diagnostics)
• SES
• Coverage of interventions (sub-national versus national programmes)
Sensitivity analysis
We will conduct sensitivity analysis narratively or statistically (for a subset of studies where meta-analysis is considered appropriate) to
investigate the influence of study quality.
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Internal sources
• KEMRI-Wellcome Trust Research Programme, Kenya.
External sources
• Effective Health Care Research Consortium, UK.
• Cochrane Effective and Practice and Organisation of Care Group, Norway.
• Evidence-to-Policy initiative (E2Pi), Global Health Group, University of California, USA.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We intended to include only randomised trials, non-randomised trials (with at least two intervention and two control sites), controlled
before-after studies (with at least two intervention and two control sites) and interrupted-time-series studies (Appendix 1).We, however,
made a post-hoc decision to include two non-randomised cluster trials (Sabot 2009; Talisuna 2012) that compared intervention sites
to only one control site (we downgraded the certainty of evidence in Sabot 2009 and acknowledged possible confounding associated
with these designs).
We added adverse effects (unintended consequences of ACT subsidies) as a secondary outcome.
We did not consider two pre-specified secondary outcomes: availability of alternative antimalarial drugs in all facilities, private and
public (including informal outlets); and prices of alternative antimalarial drugs (full adult or child courses; we prioritised direct outcomes
presented in the summary-of-findings table).
A number of methods planned in the protocol were not implemented in the review. These methods could be relevant for future updates
of this review and are summarised in Appendix 5.
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